



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C07D 263/20, 413/10, 417/10</b> <b>A61K 31/42, 31/44, 31/47</b> <b>A61K 31/425</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/09103</b>  <b>(43) International Publication Date:</b> 13 May 1993 (13.05.93)
<b>(21) International Application Number:</b> PCT/US92/08267 <b>(22) International Filing Date:</b> 5 October 1992 (05.10.92)  <b>(30) Priority data:</b> 07/786,107                      1 November 1991 (01.11.91)    US 07/831,213                      7 February 1992 (07.02.92)    US  <b>(60) Parent Applications or Grants</b> <b>(63) Related by Continuation</b> US                                      07/786,107 (CIP) Filed on                                1 November 1991 (01.11.91) US                                      07/831,213 (CIP) Filed on                                7 February 1992 (07.02.92)  <b>(71) Applicant (for all designated States except US):</b> THE UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).		<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> BARBACHYN, Michael, Robert [US/US]; 1216 Miles Avenue, Kalamazoo, MI 49001 (US). BRICKNER, Steven, Joseph [US/US]; 1304 Dogwood Drive, Portage, MI 49002 (US).  <b>(74) Agent:</b> STEELE, Gregory, W.; Corporate Intellectual Property Law, The Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).  <b>(81) Designated States:</b> AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS  <b>(57) Abstract</b>  <p>The present invention discloses novel substituted aryl- and heteroarylphenyloxazolidinones which are useful as antibacterial agents. More specifically, the substituted aryl- and heteroarylphenyloxazolidinones of the invention are characterized by oxazolidinones having an aryl or heteroaryl group at the <i>p</i>-position of the 3-phenyl ring and additional substitutions at the <i>m</i>-position(s) of the 3-phenyl ring. A compound representative of this new class of oxazolidinones is (±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES  
USEFUL AS ANTIBACTERIAL AGENTS

Field of the Invention

The present invention relates to novel substituted aryl- and heteroarylphenyloxazolidinones which are useful as anti-bacterial agents.

Background of the Invention

The oxazolidinones are a class of orally-active, synthetic antibacterial agents and there are numerous references in the art disclosing a variety of oxazolidinone derivatives. For example, there are a number of references to 3-phenyl-2-oxazolidinone compounds having one or two substitutions on the phenyl ring. References disclosing a single substitution to the phenyl ring include U.S. Patent 4,948,801; 4,461,773; 4,340,606; 4,476,136; 4,250,318; 4,128,654, and Re 29,607. Additional references to 3-[(monosubstituted)phenyl]-2-oxazolidinones can be found in EP Publication 0 312 000, Gregory, et al., J. Med. Chem. 32:1673 (1989), Gregory, et al., J. Med. Chem. 33:2569 (1990), and Wang, et al., Tetrahedron 45:1323 (1989). Compounds of this type also include the antibacterial DuP721.

3-[(di- or fused-ring substituted)phenyl]-2-oxazolidinones are reported in U.S. Patents 4,977,173, 4,921,869, and 4,801,600; EP Publications 0 316 594, 0 184 170, and 0 127 902; and PCT Applications PCT/US89/03548 and PCT/US90/06220.

We have discovered 3-[(di- and tri-substituted)phenyl]-2-oxazolidinones which are effective as antibacterial agents. The compounds of the invention are characterized by oxazolidinones having an aryl or heteroaryl group at the *p*-position of the 3-phenyl ring and additional substitution(s) at the *m*-position of the phenyl ring with radicals having an electron-withdrawing effect. These compounds are surprisingly effective as antibacterial agents, since early work by Gregory, et al, J. Med. Chem. 33:2569 (1990), suggests compounds having such radicals in the *p*-position of the phenyl ring are less effective antibacterial agents.

Synthesis of 3-phenyl-2-oxazolidinones and derivatives thereof are well known in the art. However, due to the nature of the radicals, the substituted phenyls of the invention are difficult to synthesize. Thus, we also disclose a process by which the compounds of the invention may be synthesized.

Information Disclosure

The following references disclose 3-phenyl-2-oxazolidinones having a single substitution on the phenyl ring:

U.S. Patent 4,948,801 discloses 3-[(aryl and heteroaryl)phenyl]-2-oxazolidinones having antibacterial activity.

U.S. Patent 4,476,136 discloses 3-[(*p*-arylalkyl, arylalkenyl, and arylacetylenic substituted)phenyl]-5-(aminomethyl)-2-oxazolidinones which have antibacterial activity.

U.S. Patent 4,461,773 discloses substituted 3-phenyl-5-(hydroxymethyl)-2-

oxazolidinones which have antibacterial activity.

U.S. Patent 4,340,606 discloses substituted 3-[(p-alkylsulfonyl)phenyl]-5-(hydroxymethyl)- or (acyloxymethyl)-2-oxazolidinones having antibacterial activity in mammals.

U.S. Patent 4,250,318 discloses substituted 3-phenyl-5-(hydroxymethyl)-2-oxazolidinones  
5 having antidepressive utility.

U.S. Patent 4,128,654 discloses substituted 3-phenyl-5-(halomethyl)-2-oxazolidinones which are useful in controlling fungal and bacterial diseases of plants.

U.S. Reissue Patent 29,607 discloses substituted 3 phenyl-5-(hydroxymethyl)-2-oxazolidinones having antidepressive, tranquilizing and sedative utility.

10 Belgian Patent 892,270 discloses the 3-[(arylalkyl, arylalkenyl or arylacetylenic substituted)phenyl]-5-(aminomethyl)-2-oxazolidinones corresponding to U.S. Patent 4,476,136 listed above.

European Patent Publication 0 352 781 discloses aryl and heteroaryl substituted 3-phenyl-2- oxazolidinones corresponding to U.S. Patent 4,948,801 listed above.

15 European Patent Publication 0 312 000, as reported in Chemical Abstracts 89-116142/16, discloses phenylmethyl and pyridinylmethyl substituted 3-phenyl-2-oxazolidinones.

W. A. Gregory, et al., J. Med. Chem. 33:2569 (1990) and J. Med. Chem. 32:1673 (1989); C. J. Wang, et al., Tetrahedron 45:1323 (1989); and A. M. Slee, et al. Antimicrobial Agents and Chemotherapy 1791 (1987) are additional recent references disclosing 3-[(p-  
20 substituted) phenyl]-2-oxazolidinones.

The above references do not disclose the 3-[(di- or tri-substituted)phenyl]-2-oxazolidinones of the present invention.

The following references disclose 3-[(di-substituted)phenyl]- or 3-[(fused-ring substituted)phenyl]-2-oxazolidinones:

25 U.S. Patent 4,977,173 discloses 3-phenyl-2-oxazolidinones having a lactam at the *p*-position and fluorine at the *m*-position of the phenyl ring (Formula XIII). However, the 3-[(di- or tri-substituted)phenyl]-2-oxazolidinones of the present invention have an aromatic ring at the *p*-position.

U.S. Patents 4,921,869 and 4,801,600 disclose 6'-indoliny- or alkanoneoxazolidinones  
30 (where the indoliny- nitrogen is meta to the oxazolidinone nitrogen).

U.S. Patent 4,705,799 discloses substituted aminomethyloxoxazolidinyl benzene derivatives including sulfides, sulfoxides, sulfones and sulfonamides which possess antibacterial activity. However, compounds of the present invention have an aryl or heteroaryl at the *p*-position of the phenyl ring.

35 European Patent Publication 0 316 594 discloses substituted 3-(styryl)-2-oxazolidinones corresponding to U.S. Patent 4,977,173 listed above.


European Patent Publications 0 184 170 and 0 127 902 correspond to U.S. Patent 4,705,799, discussed above.

PCT/US89/03548 and PCT/US90/06220 disclose 3-[(fused-ring substituted)phenyl]-2-oxazolidinones which are useful as antibacterial agents.

The above references do not disclose the 3-[(di- or tri-substituted)phenyl]-2-oxazolidinones of the present invention.

### SUMMARY OF THE INVENTION

Disclosed are substituted aryl- and heteroaryl-phenyl oxazolidinones of Formula (XII)



where

(I)  $R_1$  and  $R_2$  are the same or different and are selected from the group consisting of

- (a) -H,
- (b) -F,
- (c) -Cl,
- (d) -CF<sub>3</sub>, and

(e) -OCH<sub>3</sub>, provided that only one of  $R_1$  or  $R_2$  may be hydrogen;

(II)  $R_3$  is selected from the group consisting of

- (a) phenyl,
- (b) pyridyl,
- (c) pyrazinyl, (d) pyridazinyl, (e) pyrimidinyl,
- (f) 1,2,3-, (g) 1,2,4-, (h) 1,2,5-triazinyl,
- (i) quinolinyl, (j) isoquinolinyl,
- (k) quinoxalinyl, (l) quinazolinyl, (m) phthalazinyl, (n) cinnolinyl,
- (o) naphthyridinyl,
- (p) indolyl having nitrogen optionally substituted with  $R_{5-1}$  where  $R_{5-1}$  is

- H,
- C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with one or more halogens,
- C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or
- C(O) $R_{5-2}$  where  $R_{5-2}$  is

-H,

C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with one or more halogens, or  
phenyl optionally substituted with one or more halogens,

(q) pyrrolopyridinyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above, (r) furanopyridinyl, (s) thienopyridinyl,

(t) benzothiazolyl, (u) benzoxazolyl,

(v) imidazolyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

(w) pyrazolyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

(x) thiazolyl, (y) isothiazolyl,

(z) oxazolyl, (aa) isoxazolyl,

(bb) pyrrolyl having nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

(cc) furanyl, (dd) thiophenyl,

wherein substituents (a)-(dd) are optionally substituted with X and Y,

(ee) 1,2,3-, (ff) 1,2,4-triazolyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

wherein substituents (ee) and (ff) are optionally substituted with X;

(III) each occurrence of Y is independently selected from

(a) -H,

(b) -F, (c) -Cl, (d) -Br, (e) -I,

(f)  $-R_{3-1}$ , (g)  $-OR_{3-1}$ , where  $R_{3-1}$  is H or  $C_1$ - $C_4$  alkyl, or

(h)  $-NO_2$ ;

(IV) each occurrence of X is independently selected from

(a) -H,

(b)  $C_1$ - $C_8$  alkyl optionally substituted with

one or more halogens,

-OH,

=O other than at alpha position,

$-S(O)_n R_{3-2}$  where  $R_{3-2}$  is  $C_1$ - $C_4$  alkyl or  $C_3$ - $C_8$  cycloalkyl, or

$-NR_{3-3}R_{3-4}$  where  $R_{3-3}$  and  $R_{3-4}$  are the same or different and are -H,

$C_1$ - $C_8$  alkyl,  $C_3$ - $C_8$  cycloalkyl,  $-(CH_2)_t CHOR_{3-5}$ ,  $-(CH_2)_t NR_{3-6}R_{3-7}$ , or taken together are  $-(CH_2)_t O(CH_2)_t$ ,

$-(CH_2)_t CH(CO)R_{3-8}$ , or  $-(CH_2)_t N(R_{3-8})(CH_2)_2$  where

$R_{3-5}$  is -H or  $C_1$ - $C_4$  alkyl, or

$R_{3-6}$  and  $R_{3-7}$  are the same or different and are -H,  $C_1$ - $C_4$  alkyl

or taken together are  $-(CH_2)_t$ ,


(c)  $C_2$ - $C_5$  alkenyl.

-5-

- (d) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 (e) -OR<sub>3-3</sub> where R<sub>3-3</sub> is as defined above,  
 (f) -CN,  
 (g) -S-(O)<sub>n</sub>-R<sub>3-8</sub> where R<sub>3-8</sub> is  
 5 C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with  
 one or more halogens,  
 -OH,  
 -CN,  
 -NR<sub>3-3</sub>R<sub>3-4</sub> where R<sub>3-3</sub> and R<sub>3-4</sub> are as defined above, or  
 10 -CO<sub>2</sub>R<sub>3-5</sub> where R<sub>3-5</sub> is as defined above,  
 C<sub>2</sub>-C<sub>4</sub> alkenyl,  
 -NR<sub>3-9</sub>R<sub>3-10</sub> where R<sub>3-9</sub> is -H, C<sub>1</sub>-C<sub>4</sub> alkyl, or C<sub>3</sub>-C<sub>8</sub> cycloalkyl and  
 R<sub>3-10</sub> is -H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkenyl, C<sub>3</sub>-C<sub>4</sub> cycloalkyl, -OR<sub>3-5</sub>, or -NR<sub>3-6</sub>R<sub>3-7</sub> where  
 R<sub>3-5</sub>, R<sub>3-6</sub>, and R<sub>3-7</sub> are as defined above,  
 15 -N<sub>3</sub>,  
 -NHC(O)R<sub>3-11</sub> where R<sub>3-11</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with  
 one or more halogens,  
 (h) -S(O)<sub>2</sub>-N=S(O)<sub>p</sub>R<sub>3-14</sub>R<sub>3-15</sub> where R<sub>3-14</sub> and R<sub>3-15</sub> are the same or  
 different and are C<sub>1</sub>-C<sub>2</sub> alkyl, or taken together are -(CH<sub>2</sub>)<sub>q</sub>-,  
 20 (i) -S-C(O)-R<sub>3-11</sub> where R<sub>3-11</sub> is as defined above,  
 (j) tetrazoly,  
 (k) -NR<sub>3-3</sub>R<sub>3-4</sub> where R<sub>3-3</sub> and R<sub>3-4</sub> are as defined above,  
 (l) -N(R<sub>3-3</sub>)COR<sub>3-11</sub> where R<sub>3-3</sub> and R<sub>3-11</sub> are as defined above,  
 (m) -N(R<sub>3-3</sub>)S(O)<sub>n</sub>R<sub>3-11</sub> where R<sub>3-3</sub> and R<sub>3-11</sub> are as defined above,  
 25 (n) -CONR<sub>3-3</sub>R<sub>3-4</sub> where R<sub>3-3</sub> and R<sub>3-4</sub> are as defined above,  
 (o) -C(O)R<sub>3-16</sub> where R<sub>3-16</sub> is  
 -H,  
 C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with one or more halogens,  
 C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with  
 30 -OR<sub>3-5</sub>,  
 -OC(O)R<sub>3-5</sub>,  
 -NR<sub>3-3</sub>R<sub>3-4</sub>,  
 -S(O)<sub>n</sub>R<sub>3-17</sub>,  
 C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or  
 35 C<sub>2</sub>-C<sub>5</sub> alkenyl optionally substituted with -CHO or -CO<sub>2</sub>R<sub>3-5</sub>, where  
 R<sub>3-3</sub>, R<sub>3-4</sub>, and R<sub>3-5</sub> are as defined above and R<sub>3-17</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

-6-

- (p)  $-C(=NR_{3-18})R_{3-16}$  where  $R_{3-16}$  is as defined above and  $R_{3-18}$  is  $-NR_{3-3}R_{3-4}$ ,  $-OR_{3-3}$ , or  $-NHC(O)R_{3-3}$  where  $R_{3-3}$  and  $R_{3-4}$  are as defined above.
- (q)  $-CR_{3-16}(OR_{3-19})OR_{3-20}$  where  $R_{3-16}$  is as defined above and  $R_{3-19}$  and  $R_{3-20}$  are the same or different and are  $C_1-C_4$  alkyl, or taken together are  $-(CH_2)_m$ .



- where  $R_{3-3}$ ,  $R_{3-4}$ ,  $R_{3-5}$ ,  $R_{3-9}$ , and  $R_{3-16}$  are as defined above and  $R_{3-21}$  is  $R_{3-4}$  or  $-NR_{3-4}R_{3-5}$  where  $R_{3-4}$  and  $R_{3-5}$  are as defined above;

- m is 2 or 3;  
 n is 0, 1, or 2;  
 p is 0 or 1;  
 q is 3, 4, or 5;  
 t is 1, 2, or 3;

(V)  $R_4$  is selected from the group consisting of

- (a)  $-H$ ;  
 (b)  $C_1-C_{12}$  alkyl optionally substituted with 1-3 Cl,  
 (c)  $C_3-C_{12}$  cycloalkyl,  
 (d)  $C_5-C_{12}$  alkenyl containing one double bond,  
 (e) phenyl optionally substituted with 1-3  $-OH$ ,  $-OCH_3$ ,  $-OC_2H_5$ ,  $-NO_2$ ,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-COOH$  and  $-SO_3H$ ,  $-N(R_{4-1})(R_{4-2})$  where  $R_{4-1}$  and  $R_{4-2}$  are the same or different and are  $-H$  and  $C_1-C_5$  alkyl,  
 (f) furanyl,  
 (g) tetrahydrofuranyl,  
 (h) 2-thiophene,



-7-

- (i) pyrrolidinyl,
- (j) pyridinyl,
- (k) -O-R<sub>4-3</sub> where R<sub>4-3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl,
- (l) -NH<sub>2</sub>,
- 5 (m) -NHR<sub>4-4</sub> where R<sub>4-4</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl or - $\phi$ ,
- (n) -NR<sub>4-4</sub>R<sub>4-5</sub> where R<sub>4-4</sub> is as defined above and R<sub>4-5</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl, or taken together with the attached nitrogen atom to form a saturated mono-nitrogen C<sub>5</sub>-C<sub>7</sub> heterocyclic ring including -O- (morpholine),
- (o) -CH<sub>2</sub>-OH,
- 10 (p) -CH<sub>2</sub>-OR<sub>4-6</sub> where R<sub>4-6</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl or -CO-R<sub>4-7</sub> where R<sub>4-7</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl or - $\phi$ ;

and pharmaceutically acceptable salts thereof.

More particularly, the invention discloses compounds of formula (XII) where R<sub>3</sub> is a pyridyl or phenyl ring which are optionally substituted with -H, C<sub>1</sub>-C<sub>4</sub> alkyl, or -NR<sub>3-3</sub>R<sub>3-4</sub>.

- 15 Most particularly, disclosed are the compounds ( $\pm$ )-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone and ( $\pm$ )-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone.

Another aspect of the invention discloses a process for making a compound of formula (XII) comprising:

- 20 (a) converting a substituted aniline to a stabase derivative,
- (b) treating the stabase derivative to form an aryl- or heteroaryl-substituted aniline, and
- (c) converting the aryl- or heteroaryl-substituted aniline to a aryl- or heteroaryl-substituted phenyloxazolidinone.

25 More particularly, this aspect of the invention discloses a process for making a compound of formula (XII) wherein step (b) comprises treatment of the stabase derivative with an appropriate alkyl- or aryllithium to form a lithiated derivative, transmetallation with an appropriate electrophilic metal species, addition of an appropriate aryl- or heteroaryl halide or sulfonate precursor in the presence of an appropriate metal catalyst to form a protected aryl- or heteroarylaniline, and removal of the stabase protecting group with aqueous mineral acid.

- 30 Most particularly, this aspect of the invention discloses a process for making a compound of formula (XII) wherein step (b) is carried out in a one-pot reaction sequence involving deprotonation of the stabase derivative with *n*-butyllithium in tetrahydrofuran to form a lithiated derivative, transmetallation with zinc chloride, addition of an aryl- or heteroaryl-bromide, iodide, triflate, or fluorosulfonate in the presence of tetrakis(triphenylphosphine)-
- 35 palladium catalyst to form a protected aryl- or heteroaryl- aniline, and deprotection with aqueous hydrochloric acid.

Still another aspect of the invention discloses a process for making an oxazolidinone iodide comprising reacting a carbobenzyloxy allyl compound in the presence of an excess of pyridine and iodine, said excess being of equal amounts in the range of 2-20 molar equivalents.

More particularly, this aspect of the invention discloses a process for making an  
5 oxazolidinone iodide comprising reacting a carbobenzyloxy allyl compound in the presence of an excess of pyridine and iodine, wherein said excess is in the range of 5-15 molar equivalents.

Most particularly, this aspect of the invention discloses a process for making an oxazolidinone iodide comprising reacting a carbobenzyloxy allyl compound in the presence of an excess of pyridine and iodine, wherein said excess is in the range of 8-10 molar equivalents.

#### 10 DETAILED DESCRIPTION OF THE INVENTION

It is preferred that  $R_1$  or  $R_2$  are -F or -CF<sub>3</sub>; it is most preferred that  $R_1$  or  $R_2$  are -F.

It is preferred that  $R_3$  is phenyl or pyridyl; it is most preferred that  $R_3$  is 3-pyridyl or 4-pyridyl.

It is preferred that X is -H, C<sub>1</sub>-C<sub>4</sub> alkyl, or -NR<sub>3-3</sub>R<sub>3-4</sub>; it is most preferred that X is  
15 -H.

It is preferred that Y is -H or C<sub>1</sub>-C<sub>4</sub> alkyl; it is most preferred that Y is -H.

It is preferred that  $R_4$  is an acyl group optionally substituted with C<sub>1</sub>-C<sub>5</sub> alkyl optionally substituted with 1-3 halogens, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, -NR<sub>3-3</sub>R<sub>3-4</sub>, and -OR<sub>3-3</sub>; it is most preferred that  $R_4$  is -CH<sub>3</sub>.

20 It is preferred that  $R_5$  is C<sub>1</sub>-C<sub>4</sub> alkyl.

The structures of the aryl and heteroaryl groups which comprise  $R_3$  (I-XII) are shown in CHART C. Structures (o) (naphthyridinyl), (q) (pyrrolopyridinyl), (r) (furanopyridinyl), and (s) (thienopyridinyl) show the nitrogen-containing heteroaryl abbreviated as Z, where Z is an  
25 unsaturated 4-atom linker having one nitrogen and three carbons. In this way, each of the four possible positions for the heteroaryl nitrogen are encompassed by structures (o), (q), (r), and (s).

The aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the present invention are useful as antibacterial agents in treating infections in mammals caused by gram-positive and anaerobic infections. It is preferred to treat humans and warm-blooded mammals such as cattle, horses, sheep, hogs, dogs, cats, etc., with the aryl- and heteroaryl-substituted phenyl  
30 oxazolidinones (XII) of the present invention.

The aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the present invention are also useful in treating patients infected with one or more *Mycobacterium spp.* Of particular interest, the aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention are useful in treating patients infected with *M. tuberculosis* and *M. avium*.

35 The aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention can be administered in a manner and in dosage forms similar to those of the known phenyloxazoli-

dinones described above. For example, administration can be either parenteral (IV, IM, SQ) or oral. The daily dose is about 3 to about 30 mg/kg. This dose can preferably be given in divided doses and administered 2-4 times daily. The preferred route of administration as well as the particular dosage form for either the parenteral or oral route depends on the particular facts of the situation including the nature of the infection and condition of the patient. The usual pharmaceutical dosage forms appropriate for parenteral (solution, suspension in oil) and oral (tablet, capsule, syrup, suspension, etc) administration are known to those skilled in the art and there is nothing unusual about using those dosage forms with the aryl- and heteroaryl-substituted phenyloxazolidinones (XII). The exact dosage of the aryl- and heteroaryl-substituted phenyloxazolidinones (XII) to be administered, the frequency of administration, route of administration, and the dosage form will vary depending on a number of factors known to those skilled in the art including the age, weight, sex, general physical condition of the patient, the nature of the infection (particular microorganism involved, its virulence, the extent of the infection) other medical problems of the patient, etc., as is well known to the physician treating infectious diseases.

The aryl- and heteroaryl-substituted phenyloxazolidinones (XII) can be used either alone or in conjunction with other antibacterial agents as is known to those skilled in the art. Further, the aryl- and heteroaryl-substituted phenyloxazolidinones (XII) can be used in conjunction with non-antibacterial agents as is known to those skilled in the art.

Suitable pharmaceutical salts include the acid addition salts when a basic group is present, such as occurs with the preferred pyridyl group. The acid addition salts including those made from mineral acids, e.g., hydrochloric, hydrobromic, sulfuric, phosphoric, etc., organic sulfonic acids, e.g., methanesulfonic, organic carboxylic acids, e.g., amino, and carbohydrate acids, e.g., gluconic, galacturonic, etc. It is also appreciated by those skilled in the art that the appropriate N-oxides of R<sub>3</sub> heteroaryls and tertiary amino substituted aryls are included within the scope of the aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention.

The pharmaceutically active aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of this invention are prepared as described briefly here and in more detail in the examples which follow. CHART A describes the synthesis of the aryl- and heteroaryl-substituted aniline (VI) compounds.

These aniline compounds (VI) are then subsequently reacted following procedures known, or readily acquired by one skilled in the art. These subsequent procedures parallel those described in U.S. Patents 4,705,799, PCT/US90/06220, PCT/US89/03548, and W. A. Gregory, et al., J. Med. Chem., 32:1673 (1989), all of which are incorporated herein by reference. The Cardillo-Ohno reaction is discussed in Tetrahedron 43:2505 (1979) and Tetrahedron Lett. 28:3123 (1987), both of which are also incorporated herein by reference.

CHART A demonstrates a method of preparation of the aryl- and heteroaryl-substituted anilines of the invention. The starting point is a mono- or disubstituted aniline (I). These materials are readily available from a number of commercial vendors; one such vendor is Aldrich Chemical Co., Milwaukee, WI. Alternatively, the anilines (I) are known in the chemical literature and may be readily prepared by one skilled in the art. The substituted aniline (I) is treated with n-butyllithium and 1,2-bis(chlorodimethylsilyl)ethane to form the stabase (SB) derivative (II). The SB derivative (II) is converted, in a one-pot reaction sequence, to the crude aryl- and heteroaryl-substituted aniline (VI). This sequence involves slow addition of n-butyllithium to (II), resulting in the aryllithium (III). The aryllithium (III) is transmetalated with anhydrous zinc chloride in tetrahydrofuran (THF) to give an organo zinc derivative (IV). Alternatively, the transmetalation can be carried out with trimethylborate to give the corresponding boric acid, or with tributyltin chloride to give the corresponding stannane. These species react in a manner analogous to that of the organozinc derivative (IV). Addition of the appropriate aryl or heteroaryl iodide, bromide, trifluoromethane sulfonate (triflate), or fluorosulfonate and palladium catalyst, preferably, tetrakis(triphenylphosphine)palladium, followed by warming to reflux temperature gives the coupled product (V). The reaction is quenched with aqueous mineral acid, preferably hydrochloric, to give the aryl- or heteroaryl-substituted aniline (VI). The product (VI) may then be further purified following chromatographic techniques well known in the art. Alternatively, the chromatographic purification may be delayed until after the carbobenzoxy group is appended.

The remaining synthetic steps which lead to the aryl- and heteroaryl-substituted phenyl oxazolidinone (XII) of the invention are outlined in CHART B and closely parallel the procedure found in that discussed in U.S. Patent 4,705,799, PCT/US90/06220, PCT/US89/03548, and W. A. Gregory, et al., J. Med. Chem., 32:1673 (1989). Briefly, the aniline (VI) is converted to the carbobenzoxy derivative (VII) in the presence of base and THF. Alkylation of (VII) with allyl halide, preferably bromide, gives the allylated product (VIII). This intermediate (VIII) is subjected to a modified Cardillo-Ohno iodocyclocarbamation reaction wherein an excess of pyridine in combination with the iodine, is added to facilitate formation of the oxazolidinone iodide (IX). The iodocyclocarbamation reaction as disclosed by Cardillo-Ohno requires 2-3 equivalents of iodine ( $I_2$ ), whereas when synthesizing the compounds of the invention an amount of pyridine and iodine is added which is in the range of 2-20 molar equivalents of each compound. Preferably, 5-15 equivalents should be employed, most preferred is 8-10 equivalents. In addition, we have found that this process has utility in reactions where benzyl iodide is formed and the product so formed competes in the reaction for the substrate and/or product to form unwanted benzylated products. This process, then, is useful to improve yields because it is believed that the excess pyridine traps the benzyliodide to inhibit this

competitive reaction. In the synthesis of the compounds of the invention an excessive of pyridine is necessary; when pyridine is omitted from the reaction mixture essentially none of the compounds of the invention are recovered.

After the formation of the iodide (IX) purification may be accomplished following chromatography procedures known in the art. However, this is not necessary as the iodide (IX) may be directly converted to the corresponding azide (X) by treatment with sodium azide in the presence of DMF. Reduction of (X) in the presence of hydrogen, methanol or ethyl acetate, and palladium catalyst affords the amine (XI). Acetylation of the amine (XI) provides the aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention.

The aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention contain at least one chiral center. It is apparent to one skilled in the art that when one chiral center is present, the compound can exist as one of two possible optical isomers [(R) and (S) enantiomers] or a racemic mixture of both. Both individual (R) and (S) enantiomers, as well as mixtures thereof, are within the scope of aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention. In the event a second chiral center is present in the aryl- and heteroaryl-substituted phenyloxazolidinones (XII) of the invention, the resultant diastereomers, in racemic and enantiomerically enriched forms, are also within the scope of the compounds (XII) of the invention.

The enantiomer which is pharmacologically active is the enantiomer with the "S" configuration. The racemic mixture is useful in the same way and for the same purpose as the pure S-enantiomer; the difference is that twice as much racemic material must be used to produce the same effect as the pure S-enantiomer. If desired, the mixture of enantiomers is resolved by means known to those skilled in the art. It is preferable to resolve the racemic mixture at the stage of the amino compounds (XI) using methods known to those skilled in the art, see for example, Optical Resolution Procedures for Chemical Compounds, Vol 1.: Amines and Related Compounds, Paul Newman, Optical Resolution Information Center, Manhattan College, Riverdale, NY, 10471, 1978. For example, treatment of the d,l-amino mixture (XI) with an optically active acid such as (+)-tartaric acid or alternatively with (-)-tartaric acid, would yield a mixture of diastereomeric salts, which can be separated most conveniently by fractional crystallization to give a salt containing only one enantiomer of the racemic mixture. Other suitable optically active acids include, (-) dibenzoyltartaric acid, (+)-camphoric acid, (+)- and (-)-malic acid and (+)-camphor-10-sulfonic acid. By reacting the diastereomeric salt with a base one obtains the enantiomer as the free amino compound (XI). These optically pure compounds are then used in the same way as the racemic mixture.

Charts D and E depict alternative and preferred routes to enantiomerically enriched substituted aryl- and heteroarylphenyloxazolidinones of formula XII which are the subject of this

invention. It will be apparent to those skilled in the art that these are merely representative examples, and that slight modifications of the provided synthetic protocols will allow for the preparation of further enantiomerically enriched examples of the oxazolidinones of the invention.

The reaction of an isocyanate with racemic and enantiomerically enriched glycidol derivatives to give oxazolidinones is a known and facile process. (See e.g., J. E. Herweh, W. J. Kauffman, *Tetrahedron Letter.*, 809 (1971); W. A. Gregory, et al., *J. Med. Chem.*, 32:1673 (1989); W. A. Gregory, et al., *J. Med. Chem.* 33:2569 (1990); C. H. Park, et al., *J. Med. Chem.*, 35:1156 (1992); W. A. Gregory, U.S. Patent 4,705,799 (1987)). As shown in Chart D, an isocyanate of structure (1) can be reacted with commercially available (*R*)-glycidyl butyrate (see, e.g., W. E. Ladner, G. M. Whitesides; *J. Am. Chem. Soc.*, 106:7250 (1984), available from Aldrich Chemical Company, Inc.) in the presence of catalytic lithium bromide and tributylphosphine oxide and in a suitable solvent such as xylene and at a suitable temperature (e.g. reflux) to provide the oxazolidinone intermediate (2). The butyryl group is then removed by reaction with an alkoxide, preferably sodium methoxide in methanol, to furnish the key hydroxymethyloxazolidinone intermediate (3). The most preferred route to the alcohol (3) involves the deprotonation of an appropriate CBz-protected aniline of structure (4), readily prepared by standard Schotten-Baumann conditions or other variations known to one skilled in the art, with a suitable base such as *n*-butyllithium in a suitable solvent such as tetrahydrofuran and at a suitable temperature such as -78° to -60°C. Addition of the (*R*)-glycidyl butyrate, followed by warming to ambient temperature, then directly affords the hydroxymethyloxazolidinone (3), identical in all respects with material prepared via the isocyanate sequence. Compound (3) is then converted to the corresponding methanesulfonate (mesylate) or *p*-toluenesulfonate (tosylate) derivative (5) or the like, by the action of methanesulfonyl chloride/pyridine or methanesulfonyl chloride/triethylamine/dichloromethane or *p*-toluenesulfonyl chloride/pyridine. The resultant sulfonate is then reacted with an azide source, for example sodium or potassium azide, in a dipolar aprotic solvent such as *N,N*-dimethylformamide (DMF) or 1-methyl-2-pyrrolidinone optionally in the presence of a catalyst such as 18-crown-6 at a temperature of 50° to 90°C to afford the azide (6). The azide (6) is then reduced by hydrogenation with palladium on carbon or a platinum-based catalyst in an appropriate solvent such as ethyl acetate or methanol (or combinations thereof) to give the aminomethyloxazolidinone (7). Alternatively, the azide may be reduced by treatment with a trivalent phosphorus compound such as triphenylphosphine in the presence of water and in a suitable solvent such as tetrahydrofuran (THF). Compound (7) is then acylated by reactions known to those skilled in the art to give the intermediates of structure (8). Compound (8) is then iodinated with iodine monochloride in acetic acid or acetic acid/trifluoroacetic acid (see, e.g., W. A. Gregory, U.S. Patent 4,705,799 (1987)) at a temperature from 0° to 70°C or with iodine and silver trifluoro-

acetate (see e.g., W. A. Gregory, *et al.*, J. Med. Chem. 33:2569 (1990); and C. H. Park, *et al.*, J. Med. Chem., 35:1156 (1992)) to furnish the enantiomerically enriched substituted iodophenyl-oxazolidinone intermediate (9). Alternatively, (8) can be brominated with *N*-bromosuccinimide to give the corresponding bromophenyloxazolidinone of structure 9.

5 Further elaboration of the intermediates of formula (9) to make the enantiomerically enriched substituted aryl- and heteroarylphenyloxazolidinones of formula XII which are the subject of this invention is outlined in Chart E. Compound (9) is reacted with the desired aryl- or heteroaryl-substituted metal of formula  $R^3M$  ( $M$  = trialkyltin, boronic acid or ester, or halozinc) in the presence of a suitable palladium catalyst such as tetrakis(triphenylphosphine)-  
10 palladium or bis(triphenylphosphine)palladium chloride in a suitable solvent such as DMF or 1,4-dioxane at a suitable temperature (typically  $70^{\circ}$ - $100^{\circ}$ C) to afford the coupled aryl- or heteroarylphenyloxazolidinone products of structure XII. Alternatively, the iodo- or bromophenyloxazolidinone of formula (9) is converted to the corresponding trimethyltin derivative (11) by treating it with hexa-methylditin in the presence of a suitable palladium  
15 catalyst such as tetrakis(triphenylphosphine)-palladium or bis(triphenylphosphine)palladium chloride in a suitable solvent such as DMF or 1,4-dioxane at a suitable temperature (typically  $70^{\circ}$  to  $100^{\circ}$ C). Intermediate (11) is then treated with the desired aryl or heteroaryl halide of formula  $R^3X$  ( $X$  = Br or I) in the presence of a suitable palladium catalyst such as tetrakis- (triphenylphosphine)palladium or bis(triphenyl-phosphine)palladium chloride in a suitable  
20 solvent such as DMF or 1,4-dioxane at a suitable temperature (typically  $70^{\circ}$ - $100^{\circ}$ C) to afford the enantiomerically enriched aryl- or heteroaryl-phenyloxazolidinone products of structure XII which are the subject of this invention. This latter route (proceeding through 11) is exemplified in the supplemental experimental section by a racemic Example 55.

The definitions and explanations below are for the terms as used throughout this entire  
25 document including both the specification and the claims.

#### Conventions

The chemical formulas representing various compounds or molecular fragments in the specification and claims may contain variable substituents in addition to expressly defined structural features. These variable substituents are identified by a letter or a letter followed by a  
30 numerical subscript, for example, " $Z_1$ " or " $R_i$ " where " $i$ " is an integer. These variable substituents are either monovalent or bivalent, that is, they represent a group attached to the formula by one or two chemical bonds. For example, a group  $Z_1$  would represent a bivalent variable if attached to the formula  $CH_3-C(=Z_1)H$ . Groups  $R_i$  and  $R_j$  would represent monovalent variable substituents if attached to the formula  $CH_3-CH_2-C(R_i)(R_j)H_2$ . When chemical  
35 formulas are drawn in a linear fashion, such as those above, variable substituents contained in parentheses are bonded to the atom immediately to the left of the variable substituent enclosed

in parenthesis. When two or more consecutive variable substituents are enclosed in parentheses, each of the consecutive variable substituents is bonded to the immediately preceding atom to the left which is not enclosed in parentheses. Thus, in the formula above, both  $R_i$  and  $R_j$  are bonded to the preceding carbon atom.

5 Chemical formulas or portions thereof drawn in a linear fashion represent atoms in a linear chain. The symbol "-" in general represents a bond between two atoms in the chain. Thus,  $\text{CH}_3\text{-O-CH}_2\text{-CH(R}_i\text{)-CH}_3$  represents a 2-substituted-1-methoxypropane compound. In a similar fashion, the symbol "=" represents a double bond, e.g.,  $\text{CH}_2=\text{C(R}_i\text{)-O-CH}_3$ , and the symbol " $\equiv$ " represents a triple bond, e.g.,  $\text{HC}\equiv\text{C-CH(R}_i\text{)-CH}_2\text{-CH}_3$ . Carbonyl groups are  
10 represented in either one of two ways:  $\text{-CO-}$  or  $\text{-C(=O)-}$ , with the former being preferred for simplicity.

Chemical formulas of cyclic (ring) compounds or molecular fragments can be represented in a linear fashion. Thus, the compound 4-chloro-2-methylpyridine can be represented in linear fashion by  $\text{N}^*=\text{C(CH}_3\text{)-CH=CCl-CH=C}^*\text{H}$  with the convention that the  
15 atoms marked with an asterisk (\*) are bonded to each other resulting in the formation of a ring. Likewise, the cyclic molecular fragment, 4-(ethyl)-1-piperazinyl can be represented by  $\text{-N}^*-(\text{CH}_2)_2\text{-N(C}_2\text{H}_5\text{)-CH}_2\text{-C}^*\text{H}_2$ .

A rigid cyclic (ring) structure for any compounds herein defines an orientation with respect to the plane of the ring for substituents attached to each carbon atom of the rigid cyclic  
20 compound. For saturated compounds which have two substituents attached to a carbon atom which is part of a cyclic system,  $\text{-C(X}_1\text{)(X}_2\text{)-}$  the two substituents may be in either an axial or equatorial position relative to the ring and may change between axial/equatorial. However, the position of the two substituents relative to the ring and each other remains fixed. While either substituent at times may lie in the plane of the ring (equatorial) rather than above or below the  
25 plane (axial), one substituent is always above the other. In chemical structural formulas depicting such compounds, a substituent ( $\text{X}_1$ ) which is "below" another substituent ( $\text{X}_2$ ) will be identified as being in the alpha ( $\alpha$ ) configuration and is identified by a broken, dashed or dotted line attachment to the carbon atom, i.e., by the symbol "- - -" or "...". The corresponding substituent attached "above" ( $\text{X}_2$ ) the other ( $\text{X}_1$ ) is identified as being in the beta ( $\beta$ ) con-  
30 figuration and is indicated by an unbroken line attachment to the carbon atom.

When a variable substituent is bivalent, the valences may be taken together or separately or both in the definition of the variable. For example, a variable  $\text{R}_i$  attached to a carbon atom as  $\text{-C(=R}_i\text{)-}$  might be bivalent and be defined as oxo or keto (thus forming a carbonyl group ( $\text{-CO-}$ )) or as two separately attached monovalent variable substituents  $\alpha\text{-R}_{i-j}$  and  $\beta\text{-R}_{i-k}$ . When  
35 a bivalent variable,  $\text{R}_i$ , is defined to consist of two monovalent variable substituents, the convention used to define the bivalent variable is of the form " $\alpha\text{-R}_{i-j}:\beta\text{-R}_{i-k}$ " or some variant



thereof. In such a case both  $\alpha\text{-R}_{i-j}$  and  $\beta\text{-R}_{i-k}$  are attached to the carbon atom to give  $-\text{C}(\alpha\text{-R}_{i-j})(\beta\text{-R}_{i-k})-$ . For example, when the bivalent variable  $\text{R}_6$ ,  $-\text{C}(=\text{R}_6)-$  is defined to consist of two monovalent variable substituents, the two monovalent variable substituents are  $\alpha\text{-R}_{6-1}:\beta\text{-R}_{6-2}$ , ...,  $\alpha\text{-R}_{6-9}:\beta\text{-R}_{6-10}$ , etc, giving  $-\text{C}(\alpha\text{-R}_{6-1})(\beta\text{-R}_{6-2})-$ , ...,  $-\text{C}(\alpha\text{-R}_{6-9})(\beta\text{-R}_{6-10})-$ , etc. Likewise, for the bivalent variable  $\text{R}_{11}$ ,  $-\text{C}(=\text{R}_{11})-$ , two monovalent variable substituents are  $\alpha\text{-R}_{11-1}:\beta\text{-R}_{11-2}$ . For a ring substituent for which separate  $\alpha$  and  $\beta$  orientations do not exist (e.g. due to the presence of a carbon double bond in the ring), and for a substituent bonded to a carbon atom which is not part of a ring the above convention is still used, but the  $\alpha$  and  $\beta$  designations are omitted.

Just as a bivalent variable may be defined as two separate monovalent variable substituents, two separate monovalent variable substituents may be defined to be taken together to form a bivalent variable. For example, in the formula  $-\text{C}_1(\text{R}_i)\text{H}-\text{C}_2(\text{R}_j)\text{H}-$  ( $\text{C}_1$  and  $\text{C}_2$  define arbitrarily a first and second carbon atom, respectively)  $\text{R}_i$  and  $\text{R}_j$  may be defined to be taken together to form (1) a second bond between  $\text{C}_1$  and  $\text{C}_2$  or (2) a bivalent group such as oxa ( $-\text{O}-$ ) and the formula thereby describes an epoxide. When  $\text{R}_i$  and  $\text{R}_j$  are taken together to form a more complex entity, such as the group  $-\text{X}-\text{Y}-$ , then the orientation of the entity is such that  $\text{C}_1$  in the above formula is bonded to  $\text{X}$  and  $\text{C}_2$  is bonded to  $\text{Y}$ . Thus, by convention the designation "...  $\text{R}_i$  and  $\text{R}_j$  are taken together to form  $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CO}-$  ..." means a lactone in which the carbonyl is bonded to  $\text{C}_2$ . However, when designated "...  $\text{R}_j$  and  $\text{R}_i$  are taken together to form  $-\text{CO}-\text{O}-\text{CH}_2-\text{CH}_2-$  the convention means a lactone in which the carbonyl is bonded to  $\text{C}_1$ .

The carbon atom content of variable substituents is indicated in one of two ways. The first method uses a prefix to the entire name of the variable such as " $\text{C}_1\text{-C}_4$ ", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable. The prefix is separated from the variable by a space. For example, " $\text{C}_1\text{-C}_4$  alkyl" represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given). Whenever this single prefix is given, the prefix indicates the entire carbon atom content of the variable being defined. Thus  $\text{C}_2\text{-C}_4$  alkoxy-carbonyl describes a group  $\text{CH}_3-(\text{CH}_2)_n-\text{O}-\text{CO}-$  where  $n$  is zero, one or two. By the second method, the carbon atom content of only each portion of the definition is indicated separately by enclosing the " $\text{C}_i\text{-C}_j$ " designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined. By this optional convention ( $\text{C}_1\text{-C}_3$ )alkoxycarbonyl has the same meaning as  $\text{C}_2\text{-C}_4$  alkoxy-carbonyl because the " $\text{C}_1\text{-C}_3$ " refers only to the carbon atom content of the alkoxy group. Similarly while both  $\text{C}_2\text{-C}_6$  alkoxyalkyl and ( $\text{C}_1\text{-C}_3$ )alkoxy( $\text{C}_1\text{-C}_3$ )alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions differ since the former definition allows either the alkoxy or alkyl portion

alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.

#### Definitions

All temperatures are in degrees Centigrade.

5 TLC refers to thin-layer chromatography.

Brine refers to an aqueous saturated sodium chloride solution.

DMF refers to N,N-dimethylformamide.

THF refers to tetrahydrofuran.

CBZ refers to carbobenzyloxy.

10 n-BuLi refers to n-butyl lithium

SG refers to silica gel.

IR refers to infrared spectroscopy.

$^1\text{H}$ -NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm ( $\delta$ ) downfield from tetramethylsilane.

15  $\phi$  refers to phenyl ( $\text{C}_6\text{H}_5$ ).

MS refers to mass spectrometry expressed as m/e or mass/charge unit.

$[\text{M} + \text{H}]^+$  refers to the positive ion of a parent plus a hydrogen atom.

EI refers to electron impact.

CI refers to chemical ionization.

20 FAB refers to fast atom bombardment.

Ether refers to diethyl ether.

Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.

When solvent pairs are used, the ratios of solvents used are volume/volume (v/v).

When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).

Examples Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.

Preparation 1 N,N-[1,2-Bis(dimethylsilyl)ethane]-3,5-difluoroaniline

-17-

A flame dried, 500 mL, 3-necked, round-bottomed flask is fitted with a Claisen tube, mechanical stirrer and a low-temperature thermometer. The flask is loaded with 8.64 g (66.9 mmol) of the starting difluoroaniline. The Claisen tube is fitted with a gas inlet adapter and a rubber septa. The starting material is placed under an atmosphere of nitrogen and 135 mL of anhydrous THF is added. The resulting solution is cooled in a dry ice-isopropanol bath and stirred mechanically. To the cold reaction solution is slowly added 88 mL (141 mmol, 2.1 eq) of n-BuLi (1.6M in hexanes). The reaction temperature is maintained between -70 and -40°C during the addition. After an additional 20 min, 14.4 g (66.9 mmol, 1eq) of 1,2-bis(chloro-dimethylsilyl)ethane in 135 mL of anhydrous THF is slowly added. The homogenous solution is allowed to stir for an additional 45 min and then warmed to room temperature. The reaction is carefully quenched with 200 mL of water and extracted with diethyl ether (4x200 mL). The combined organics are washed with brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to a tan, waxy solid (19.6 g). The crude material is purified by sublimation (5 torr, 40°C). 11.8 g (65%) of the title compound is recovered as a white solid (MP: 71-72°C).

Anal. Calc'd for  $C_{12}H_{19}F_2NSi_2$ : C, 53.10; H, 7.05; N, 5.15

Found: C, 52.04; H, 7.33; N, 4.99

FTIR(neat):  $cm^{-1}$  2958, 2928, 1626, 1581, 1476, 1453, 1345, 1248, 995.

MS(EI): m/z(rel. int.) 271[ $M^+$ ](28), 256(100), 228(11), 73(10).

$^1H$ -NMR( $CDCl_3$ ):  $\delta$  6.36(dd, 2H,  $J_{HF}$ =8.1 Hz,  $J_{HH}$ =2.1 Hz), 6.29(dd, 1H,  $J_{HF}$ =9.0 Hz,  $J_{HH}$ =2.1 Hz), 0.85(s, 4H), 0.25(s, 12H).

#### Preparation 2 4-(3-Pyridyl)-3,5-difluoroaniline

A flame dried, 3-necked, round-bottomed flask is loaded with 1.82 g (6.72 mmol) of the protected aniline (Preparation 1) and fitted with a rubber septa, low-temperature thermometer and a gas inlet adapter. The starting material is placed under an atmosphere of nitrogen and 27 mL of anhydrous THF is added. The resulting solution is cooled to -70°C. To the cold solution is added 5.03 mL (8.06 mmol, 1.2 eq) of n-BuLi (1.6M in hexanes) via a syringe pump (0.12 mL/min). After the addition is complete, the yellow reaction solution is allowed to stir for an additional 20 min and then 8.06 mL (8.06 mmol, 1.2 eq) of zinc chloride (1.0 M in THF) is added. The reaction is warmed to -40 °C for 15 min. To the yellow solution is added 773 mg (0.672 mmol, 0.10 eq) of  $Pd(PPh_3)_4$  in 50 mL of THF followed by 647  $\mu$ L (6.72 mmol, 1.0 eq) of 3-bromopyridine. The cooling bath is removed and the reaction is warmed to room temperature. The thermometer is replaced with a condenser and the septa with a glass stopper. The reaction is heated to reflux temperature for 16 h. After this time, the reaction is quenched with 100 mL of 10% HCl(aq). The resulting suspension is vigorously stirred for 0.5 h and then washed with diethyl ether (3x50 mL). The recovered aqueous layer is adjusted to pH 14 with 50% sodium hydroxide (aq) and then extracted with (4x50 mL). The combined organics are

washed with brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to yellow solid (935 mg). This crude material is purified by silica gel chromatography (200 g of SG, eluted with 1 L x 5% CH<sub>3</sub>CN/CHCl<sub>3</sub>, 1 L x 10% CH<sub>3</sub>CN/CHCl<sub>3</sub>, 1 L x 15% CH<sub>3</sub>CN/CHCl<sub>3</sub>). 625 mg (43%) of the title compound is recovered as a white solid (MP: 141-142°C).

5 Anal. Calc'd for C<sub>11</sub>H<sub>8</sub>F<sub>2</sub>N<sub>2</sub>: C, 64.08; H, 3.91; N, 13.59

Found: C, 63.92; H, 3.74; N, 13.24

FTIR(mull): cm<sup>-1</sup> 3141, 1634, 1460, 1164, 1012, 708.

MS(EI): m/z(rel. int.) 206[M<sup>+</sup>](100), 205(7), 179(5), 158(4), 89(4).

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): δ 8.67(s, 1H), 8.55(dd, 1H, J=4.9, 1.7 Hz), 7.75(dm, 1H, J=8.1 Hz),  
10 7.35(ddd, 1H, 7.8, 4.9, 0.8 Hz), 6.31(ddd, 2H, J<sub>HF</sub>=9.8, 1.5 Hz, J<sub>HH</sub>=3.7 Hz), 4.01(s(b), 2H).

### Preparation 3 N-Carbobenzyloxy-4-(3-pyridyl)-3,5-difluoroaniline

In 60 mL of dry THF is combined 625 mg (3.03 mmol) of the starting amine (Preparation 2) and 382 mg (4.55 mmol, 1.5 eq) of sodium bicarbonate. The resulting mixture is placed under an atmosphere of nitrogen and 394 μL (4.55 mmol, 1.5 eq) of benzylchloro-  
15 formate is added. The reaction is allowed to stir at room temperature for 16 h. After this time, the reaction is added to 150 mL of methylene chloride and washed with saturated sodium bicarbonate then brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to a white solid (1.09 g). The material is purified by silica gel chromatography (200 g of SG, eluted with 1 L x 3% CH<sub>3</sub>CH/CHCl<sub>3</sub>, 2 L x 5% CH<sub>3</sub>CN/CHCl<sub>3</sub>) 990 mg (96%) of the title  
20 compound is recovered as a white solid (MP 188-190°C).

FTIR (neat): cm<sup>-1</sup> 3030, 1737, 1642, 1478, 1408, 1231, 1029, 723.

Anal. calc'd for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: C, 67.06; H, 4.15; N, 8.23

Found: C, 66.18; H, 4.22; N, 7.34

MS (EI): m/z (rel. int.): 340 [M<sup>+</sup>] (21), 296 (5), 232 (4), 205 (2), 91 (100), 79 (3).

25 <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.59 (s(b), 1H), 8.53-8.51 (m, 1H), 7.95-7.92 (m, 1H), 7.56-7.51 (m, 1H), 7.44-7.31 (m, 5H), 7.28 (d, 2H, J<sub>HF</sub>=10.4 Hz), 5.21 (s, 2H).

### Preparation 4 N-Allyl-N-carbobenzyloxy-4-(3-pyridyl)-3,5-difluoroaniline

A solution of 543 mg (1.60 mmol) of the starting carbamate (Preparation 3) in 40 mL of anhydrous THF is treated with 128 mg (3.19 mmol, 2 eq) of sodium hydride (60% dispersion in  
30 mineral oil). The reaction is kept under an atmosphere of nitrogen at room temperature for 0.5 h. After this time, 691 μL (7.99 mmol, 5 eq) of allyl bromide is added. Stirring is continued at room temperature for 16 h. After this time, the reaction is carefully quenched with 20 mL of water. The layers are separated and the aqueous layer is extracted with ethyl acetate (3 x 25 mL). The combined organics are washed with brine, dried (sodium sulfate), filtered and  
35 concentrated under reduced pressure to a dark amber oil. This material is purified by silica gel chromatography (125 g of SG, eluted with 1 L x 3% CH<sub>3</sub>CN/CHCl<sub>3</sub>) 497 mg (82%) of the title

compound is recovered as a yellow solid. An analytical sample is prepared by preparative TLC (SG, 6% CH<sub>3</sub>CN/CHCl<sub>3</sub>). The analytical sample is recovered as a white solid (MP 92-93°C).

FTIR (mull): cm<sup>-1</sup> 3068, 3061, 1710, 1705, 1643, 1635, 1412, 1263, 1024, 733.

Anal. calc'd for: C<sub>22</sub>H<sub>18</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: C, 69.47; H, 4.77; N, 7.36

5

Found: C, 68.38; H, 4.83; N, 7.19

MS (EI): m/z (rel. int.) 380 [M<sup>+</sup>] (15), 336 (4), 309 (3), 245 (4), 91 (100), 65 (6).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.72 (s, 1H), 8.62 (s (b), 1H), 7.99 (d, 1H, J=7.8 Hz), 7.42-7.36 (m, 6H), 7.03 (d, 2H, J<sub>HF</sub>=9.2 Hz), 5.94 (ddt, 1H, J=11.7, 10.4, 5.2 Hz), 5.23-5.18 (m, 4H), 4.34 (d, 2H, J=5.4 Hz).

10 Preparation 5 (±)-5-(Iodomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone

In 25 mL of chloroform is combined 496 mg (1.31 mmol) of Preparation 4, 1.58 mL (19.6 mmol, 15 eq) of pyridine and 4.97 g (19.6 mmol, 15 eq) of I<sub>2</sub>. The resulting mixture is placed under an atmosphere of nitrogen and heated to 50°C with stirring. After 1.5 h, the reaction is decanted into 70 mL of chloroform. The remaining sludge is rinsed with chloroform  
15 (3x15 mL). The combined organics are washed with 20% sodium thiosulfate then brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to a yellow, solid foam (491 mg). This material is purified by silica gel chromatography (100 g of SG, eluted with 1L x 0.5% MeOH/CHCl<sub>3</sub>, 1 L x 1% MeOH/CHCl<sub>3</sub>). 269 mg (49%) of the title compound is recovered as a yellow solid (MP 133-134°C).

20

FTIR (mull): cm<sup>-1</sup> 3130, 1758, 1650, 1414, 1241, 1017, 846.

Anal. calc'd for C<sub>15</sub>H<sub>11</sub>F<sub>2</sub>IN<sub>2</sub>O<sub>4</sub>: C, 43.29; H, 2.66; N, 6.73

Found: C, 43.19; H, 2.56; N, 6.59

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.72 (s, 1H), 8.62 (s(b), 1H), 7.79 (d, 1H, J=10.7 Hz), 7.43-7.38 (m, 1H), 7.32 (d, 2H, J<sub>HF</sub>=9.9 Hz), 4.84-4.72 (m, 1H), 4.19 (dd, 1H, J=8.9, 8.9 Hz), 3.80 (dd,  
25 1H, J=6.0, 9.2 Hz), 3.51 (dd, 1H, J=3.8, 10.5 Hz), 3.39 (dd, 1H, J=8.2, 10.5 Hz).

Preparation 6 (±)-5-(Azidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone

In 15 mL of DMF (dried over 4A sieves) is combined 577 mg (1.31 mmol) of the starting iodide (Preparation 5) and 681 mg (10.5 mmol, 8 eq) of sodium azide. The reaction is placed under an atmosphere of nitrogen and heated to 55°C. After 2 h, the reaction is added to  
30 100 mL of water and then extracted with ethyl acetate (4x25 mL). The combined organics are washed with water then brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to an amber oil (354 mg, 82% crude yield). The crude azide is suitable for reduction without further purification. An analytical sample is prepared by preparative TLC (SG, 10% CH<sub>3</sub>CN/CHCl<sub>3</sub>). 22 mg of the title compound is recovered as an off white solid (MP 97-98°C).

35

FTIR (mull): cm<sup>-1</sup> 3483, 2110, 1746, 1640, 1417, 1237, 1064, 716.

Anal. calc'd for C<sub>15</sub>H<sub>11</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>: C, 54.38; H, 3.35; N, 21.14

-20-

Found: C, 54.33; H, 3.38; N, 19.39

MS (EI): m/z (rel. int.): 331 [ $M^+$ ] (100), 274 (14), 258 (23), 232 (15), 217 (22), 190 (22), 43 (14).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.72 (s(b), 1H), 8.63 (s(b), 1H), 7.79 (d, 1H,  $J=7.9$  Hz), 7.42-7.38 (m, 1H), 7.34 (d, 2H,  $J_{\text{HF}}=9.9$  Hz), 4.90-4.82 (m, 1H), 4.11 (dd, 1H,  $J=8.9, 8.9$  Hz), 3.88 (dd, 1H,  $J=6.2, 8.9$  Hz), 3.77 (dd, 1H,  $J=4.4, 13.4$  Hz), 3.63 (dd, 1H,  $J=4.1, 13.3$  Hz).

**Preparation 7** ( $\pm$ )-5-(Aminomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone

In 40 mL of methanol is combined 354 mg (~1.07 mmol) of the crude azide (Preparation 6) and 50 mg of 10% pd-C. The mixture is purged with nitrogen and then placed under an atmosphere of hydrogen (1 atm). The reaction is allowed to stir at room temperature for 16 h. After this time, the reaction is filtered and concentrated under reduced pressure to an amber solid foam (291 mg, ~89% crude). The crude amine is suitable for acetylation without further purification. An analytical sample is prepared by preparative TLC (SG, 10% MeOH/ $\text{CHCl}_3$ ). The title compound is recovered as a white solid (MP 143-145°C).

FTIR (neat)  $\text{cm}^{-1}$  3368 (b), 1757, 1646, 1412, 1244, 1025, 714.

Anal. calc'd for  $\text{C}_{15}\text{H}_{13}\text{F}_2\text{N}_3\text{O}_2$ : C, 59.02; H, 4.29; N, 13.76

Found: C, 57.94; H, 4.21; N, 13.13

MS(EI): m/z (rel. int.) 305 [ $M^+$ ] (67), 276 (15), 233 (66), 219 (12), 44 (13), 29 (100).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.71 (s, 1H), 8.62 (dd, 1H,  $J=1.6, 4.9$  Hz), 7.79 (d, 1H,  $J=8.1$  Hz), 7.39 (dd, 1H,  $J=4.9, 8.0$  Hz), 7.33 (d, 2H,  $J_{\text{HF}}=10.0$  Hz), 4.79-4.70 (m, 1H), 4.06 (dd, 1H,  $J=8.7, 8.7$  Hz), 3.92 (dd, 1H,  $J=6.7, 8.6$  Hz), 3.18 (dd, 1H,  $J=3.9, 14$  Hz), 2.98 (dd, 1H,  $J=5.3, 14$  Hz), 1.52 (s (b), 2H).

**Preparation 8** 4-(4-pyridyl)-3,5-difluoroaniline

In a manner similar to that described previously for Preparation 2, 2.00 g (7.38 mmol) of Preparation 1 is transmetalated and combined with  $\text{Pd}(\text{PPh}_3)_4$  (0.1 eq) and 4-bromopyridine (1 eq). The 4-bromopyridine is freshly prepared from the HCl salt as described below. The salt is neutralized in excess saturated sodium bicarbonate. The free base is then extracted with diethyl ether. The combined organics are dried over magnesium sulfate for 15 min, filtered, then concentrated under reduced pressure to a yellow oil. The free base is stored in a stoppered flask, under nitrogen and frozen in dry ice prior to use. The free base quickly decomposes at room temperature. The reaction is worked up as previously described. 889 mg of the crude product is isolated.  $^1\text{H}$  NMR showed this material to be a mixture of desired product and its zinc chloride complex (~1:1). An analytical sample is prepared by preparative TLC (SG, 10%  $\text{CH}_3\text{CN}/\text{CHCl}_3$ ).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.63 (dd, 2H,  $J=1.6, 4.6$  Hz), 7.38 (dd, 2H, 1.7, 4.7 Hz), 6.30 (ddd, 2H,  $J_{\text{HF}}=6.6, 10.3$  Hz,  $J_{\text{HH}}=8.7$  Hz), 4.06 (s(b), 2H).

Preparation 9 N-Carbobenzyloxy-4-(4-pyridyl)-3,5-difluoroaniline

In a manner to that previously described for Preparation 3, 236 mg (1.15 mmol) of the starting amine (Preparation 8) is converted to the carbamate derivative. The crude product is purified by silica gel chromatography (100 g of SG, eluted with a 3-5% CH<sub>3</sub>CN/CHCl<sub>3</sub> gradient). 171 mg (44%) of the title compound is recovered as a white solid.

MP: 185-186°C.

FTIR (neat): cm<sup>-1</sup> 1743, 1642, 1605, 1254, 1072.

HRMS: calc'd for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: 340.1023. Found: 340.1029.

MS (EI): m/z (rel. int.): 340 [M<sup>+</sup>] (12), 232 (16), 108 (7), 91 (100), 79 (9), 43 (28).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.67 (s(b), 2H), 7.43-7.38 (m, 7H), 7.15 (d, 2H, J<sub>HF</sub>=9.9 Hz), 5.23 (s, 2H).

Preparation 10 N-Allyl-N-carbobenzyloxy-4-(4-pyridyl)-3,5-difluoroaniline

In a manner similar to that previously described for Preparation 4, 468 mg (1.38 mmol) of the starting carbamate (Preparation 9) is allylated. The crude product is purified by silica gel chromatography (125 g of SG, eluted with 2 L x 3% CH<sub>3</sub>CN/CHCl<sub>3</sub>). 216 mg (41%) of the title compound is recovered as yellow solid.

MP: 82-83°C.

FTIR (neat): cm<sup>-1</sup> 1713, 1635, 1598, 1396, 1312, 1235, 1028.

Anal. calc'd for C<sub>22</sub>H<sub>18</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: C, 69.47; H, 4.77; N, 7.36. Found: C, 69.06; H, 4.80; N, 7.31.

MS (EI): m/z (rel. int.) 380 [M<sup>+</sup>] (16), 330 (6), 246 (26), 219 (13), 91 (100), 40 (16).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.69 (d, 2H, J=5.3 Hz), 7.41-7.33 (m, 7H), 7.03 (d, 2H, J<sub>HF</sub>=9.6 Hz), 5.92 (ddt, 1H, J=11.8, 10.4, 5.3 Hz), 5.25-5.17 (m, 4H), 4.34 (d, 2H, J=5.4 Hz).

Preparation 11 (±)-5-Iodomethyl-3-[4-(4-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone

In a manner to that previously described, 241 mg (0.634 mmol) of the cyclization precursor (Preparation 10) is converted to the oxazolidinone iodide. The crude product is not purified further.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.70 (s(b), 2H), 7.44 (d, 2H, J=5.5 Hz), 7.32 (d, 2H, J<sub>HF</sub>=10.2 Hz), 4.85-4.73 (m, 1H), 4.19 (dd, 1H, J=9.0, 9.0 Hz), 3.80 (dd, 1H, J=6.1, 9.2 Hz), 3.50 (dd, 1H, J=6.1, 10.5 Hz), 3.40 (dd, 1H, J=8.0, 10.5 Hz).

EXAMPLE 1 (±)-5-(Acetamidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone

In 10 mL of anhydrous methylene chloride is combined 135 mg (0.433 mmol) of the starting amine (Preparation 7), 143 μL (1.77 mmol, 4 eq.) of pyridine and 167 μL (1.77 mmol, 4 eq.) of acetic anhydride. The reaction is allowed to stir at room temperature under nitrogen. After 2.5 h the reaction is added to 30 mL of methylene chloride and washed with saturated sodium bicarbonate then brine, dried (sodium sulfate), filtered and concentrated under reduced

pressure to a yellow solid (138 mg). This material is purified by silica gel chromatography (70 g of SG, eluted with 1-4% MeOH/CHCl<sub>3</sub> gradient), 109 mg (71%) of the title compound is recovered as a white solid (MP 218-219°C).

FTIR (mull): cm<sup>-1</sup> 3347, 1742, 1679, 1648, 1563, 1409, 1247, 1022, 755.

5      Anal. calc'd for C<sub>17</sub>H<sub>15</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>:      C, 58.79; H, 4.35; N, 12.10

Found:      C, 57.29; H, 4.35; N, 11.73

MS (EI): m/z (rel. int.) 347 [M<sup>+</sup>] (100), 303 (47), 275 (42), 244 (37), 219 (61), 73 (36), 56 (52).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.68 (s(b), 1H), 8.59 (s(b), 1H), 7.85 (d, 1H, J=7.9 Hz), 7.48-7.41 (m, 2H), 7.31 (ddd, 2H, J<sub>HF</sub>=3 Hz, 13.2 Hz, J<sub>HH</sub>=7.7 Hz), 4.87-4.79 (m, 1H), 4.10 (dd, 1H, J=9.1, 9.1 Hz), 3.82 (dd, 1H, J=6.7, 9.2 Hz), 3.72-3.57 (m, 2H), 2.03 (s, 3H).

EXAMPLE 1a      (±)-5-(Acetamidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone, methanesulfonic acid salt

In 4 mL of methanol is combined 74 mg (0.21 mmol) of (±)-5-(acetamidomethyl)3-[4-(3-pyridyl)]-3,5-difluorophenyl-2-oxazolidinone (EXAMPLE 1) and 14 µL (0.21 mmol) of CH<sub>3</sub>SO<sub>3</sub>H. The mixture is warmed to reflux temperature for 3 min and the reaction becomes homogeneous. The reaction is cooled to room temperature and concentrated under reduced pressure then *in vacuo* to an amber, gummy solid. The recovered solid is triturated with and the recovered yellow solid (80 mg) is dissolved in 8 mL of water, filtered and lyophilized. 55 mg (58%) of the title compound is recovered as a yellow, hygroscopic solid (MP 203-205°C).

EXAMPLE 2      (±)-5-(acetamidomethyl)3-[4-(4-pyridyl)]-3,5-difluorophenyl-2-oxazolidinone

In 10 mL of DMF (dried over 4A sieves) is combined 213 mg of Preparation 11 and 166 mg (2.56 mmol, ~5 eq) of sodium azide. The reaction is placed under an atmosphere of nitrogen and heated to 55°C. After 2 h, the reaction is complete by TLC (6% CH<sub>3</sub>CN/CHCl<sub>3</sub>). The reaction is added to 50 mL of water and extracted with ethyl acetate (5 x 25 mL). The combined organics are washed with water, then brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to an amber oil (CAUTION: Azides are known to decompose explosively). The crude material is combined with 20 mL of methanol and 30 mg of 10% Pd-C. The reaction is purged with nitrogen then placed under an atmosphere of hydrogen. After 16 h, the reaction is filtered and concentrated under reduced pressure to a white solid. This material is combined with 64 µL of acetic anhydride and 55 µL of pyridine in 11 mL of methylene chloride. The reaction is allowed to stir at room temperature under nitrogen for 12 h. After this time, the reaction is added to 50 mL of methylene chloride and washed with saturated sodium bicarbonate then brine, dried (sodium sulfate), filtered and concentrated under reduced pressure to an amber oil. The final product is purified by silica gel chromatography (100 g of SG, eluted with a 1-4% MeOH/CHCl<sub>3</sub> gradient). 103 mg of the title



compound is recovered as a yellow solid (47% over 4 steps) (MP 147-149°C.).

FTIR (neat):  $\text{cm}^{-1}$  1741, 1651, 1646, 1412, 1246, 1027, 745.

Anal. calc'd for  $\text{C}_{17}\text{H}_{15}\text{F}_2\text{N}_3\text{O}_3$ : C, 58.79; H, 4.35; N, 12.10

Found: C, 57.53; H, 4.48; N, 11.65

5 MS (EI): m/z (rel. int.) 347 [ $\text{M}^+$ ] (28), 303 (37), 243 (46), 219 (44), 206 (57), 58 (71), 29 (100).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  8.70 (d, 2H,  $J=5.6$  Hz), 7.42 (d, 2H,  $J=6.1$  Hz), 7.29 (d, 2H,  $J_{\text{HF}}=10.3$  Hz), 6.10 (s(b), 1H), 4.90-4.78 (m, 1H), 4.08 (dd, 1H,  $J=9.1, 9.1$  Hz), 3.82 (dd, 1H,  $J=6.7, 9.2$  Hz), 3.73-3.67 (m, 2H), 2.05 (s, 3H).

#### 10 EXAMPLES 3-54

Following the general procedure of Preparations 1-11 and the above EXAMPLES, and (i) starting with the aniline REAGENT (I) listed below for each example, and (ii) using the appropriate aryl or heteroaryl iodide, bromide, triflate or fluorosulfonate for the palladium-mediated coupling reaction ( $\text{IV} \rightarrow \text{V}$ ), the TITLE COMPOUND for the respective EXAMPLE is

15 obtained.

EXAMPLE	REAGENT	TITLE COMPOUND
3	3,5-difluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(2,6-dimethylpyridin-4-yl)-3,5-difluorophenyl]-2-oxazolidinone
4	3,5-difluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(2-methylpyridin-4-yl)-3,5-difluorophenyl]-2-oxazolidinone
5	3,5-difluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(2-ethylpyridin-4-yl)-3,5-difluorophenyl]-2-oxazolidinone
6	3,5-difluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-(4-phenyl-3,5-difluorophenyl)-2-oxazolidinone
7	3,5-difluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(4-(dimethylamino)phenyl)-3,5-difluorophenyl]-2-oxazolidinone
8	3,5-dichloroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-dichlorophenyl]-2-oxazolidinone
9	3,5-dichloroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-dichlorophenyl]-2-oxazolidinone
10	3,5-dichloroaniline	( $\pm$ )-5-(acetamidomethyl)-3-(4-phenyl-3,5-dichlorophenyl)-2-oxazolidinone
11	3-fluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-fluorophenyl]-2-oxazolidinone
12	3-fluoroaniline	( $\pm$ )-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-fluorophenyl]-2-oxazolidinone

-24-

	13	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2,6-dimethylpyridin-4-yl)-3-fluorophenyl]-2-oxazolidinone
	14	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-methylpyridin-4-yl)-3-fluorophenyl]-2-oxazolidinone
5	15	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-ethylpyridin-4-yl)-3-fluorophenyl]-2-oxazolidinone
	16	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-(4-phenyl-3-fluorophenyl)-2-oxazolidinone
	17	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(4-(dimethylamino)phenyl)-3-fluorophenyl]-2-oxazolidinone
10	18	3-chloroaniline	(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-chlorophenyl]-2-oxazolidinone
	19	3-chloroaniline	(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-chlorophenyl]-2-oxazolidinone
15	20	3-chloroaniline	(±)-5-(acetamidomethyl)-3-(4-phenyl-3-chlorophenyl)-2-oxazolidinone
	21	3,5-bis(trifluoromethyl)aniline	(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-bis(trifluoromethyl)phenyl]-2-oxazolidinone
20	22	3,5-bis(trifluoromethyl)aniline	(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-bis(trifluoromethyl)phenyl]-2-oxazolidinone
	23	3,5-bis(trifluoromethyl)aniline	(±)-5-(acetamidomethyl)-3-[4-phenyl-3,5-bis(trifluoromethyl)phenyl]-2-oxazolidinone
25	24	3-(trifluoromethyl)aniline	(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-(trifluoromethyl)phenyl]-2-oxazolidinone
	25	3-(trifluoromethyl)aniline	(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-(trifluoromethyl)phenyl]-2-oxazolidinone
30	26	3-(trifluoromethyl)aniline	(±)-5-(acetamidomethyl)-3-[4-phenyl-3-(trifluoromethyl)phenyl]-2-oxazolidinone
35	27	3,5-dimethoxyaniline	(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-dimethoxyphenyl]-2-oxazolidinone

-25-

	28	3,5-dimethoxyaniline	(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-dimethoxyphenyl]-2-oxazolidinone
	29	3,5-dimethoxyaniline	(±)-5-(acetamidomethyl)-3-(4-phenyl-3,5-dimethoxyphenyl)-2-oxazolidinone
5	30	<i>m</i> -anisidine	(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-methoxyphenyl]-2-oxazolidinone
	31	<i>m</i> -anisidine	(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-methoxyphenyl]-2-oxazolidinone
	32	<i>m</i> -anisidine	(±)-5-(acetamidomethyl)-3-(4-phenyl-3-methoxyphenyl)-2-oxazolidinone
10	33	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(5-indolyl)-3,5-difluorophenyl]-2-oxazolidinone
	34	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(3-quinolyl)-3,5-difluorophenyl]-2-oxazolidinone
15	35	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(4-quinolyl)-3,5-difluorophenyl]-2-oxazolidinone
	36	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(6-quinolyl)-3,5-difluorophenyl]-2-oxazolidinone
	37	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(4-isoquinolyl)-3,5-difluorophenyl]-2-oxazolidinone
20	38	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(1-methyl-5-indolyl)-3,5-difluorophenyl]-2-oxazolidinone
	39	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(6-benzothiazolyl)-3,5-difluorophenyl]-2-oxazolidinone
25	40	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(6-benzoxazolyl)-3,5-difluorophenyl]-2-oxazolidinone
	41	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-dimethylamino)-4-thiazolyl]-3,5-difluorophenyl]-2-oxazolidinone
	42	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-thiazolyl)-3,5-difluorophenyl]-2-oxazolidinone
30	43	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-(dimethylamino)-4-oxazolyl)-3,5-difluorophenyl]-2-oxazolidinone
	44	3,5-difluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-oxazolyl)-3,5-difluorophenyl]-2-oxazolidinone
35	45	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(3-quinolyl)-3-fluorophenyl]-2-oxazolidinone

-26-

	46	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(4-quinolyl)-3-fluorophenyl]-2-oxazolidinone
	47	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(6-quinolyl)-3-fluorophenyl]-2-oxazolidinone
5	48	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(4-isoquinolyl)-3-fluorophenyl]-2-oxazolidinone
	49	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(5-indolyl)-3-fluorophenyl]-2-oxazolidinone
	50	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(1-methyl-5-indolyl)-3-fluorophenyl]-2-oxazolidinone
10	51	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(6-benzothiazolyl)-3-fluorophenyl]-2-oxazolidinone
	52	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(6-benzoxazolyl)-3-fluorophenyl]-2-oxazolidinone
15	53	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-thiazolyl)-3-fluorophenyl]-2-oxazolidinone
	54	3-fluoroaniline	(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-oxazolyl)-3-fluorophenyl]-2-oxazolidinone

Preparation 12 (R)-[3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl butyrate

20 A mixture of lithium bromide (0.181 g, 2.08 mmol), tri-*n*-butylphosphine oxide (0.454 g, 2.08 mmol), and dry *o*-xylene (10 mL) is azeotropically dried for 1 h. After cooling below the reflux point, a solution of (*R*)-glycidyl butyrate (5.000 g, 34.68 mmol) and 3-fluorophenyl isocyanate (4.755 g or 3.96 mL, 34.68 mmol) in dry *o*-xylene (10 mL) is added over 10 min to the hot solution (some refluxing observed during the addition). When the addition is complete, 25 the solution is heated to reflux for 2 h and then allowed to cool to room temperature. The solvent is removed in vacuo and the residue chromatographed over silica gel, eluting with hexane/ethyl acetate (6:1, 4:1, and then 2:1), to afford 8.758 g (90%) of the title compound as a colorless syrup with the following characteristics:

$[\alpha]_D^{25} -46.7^\circ$  (c 1.0, CHCl<sub>3</sub>).

30 IR (mineral oil mull): 1758, 1615, 1591, 1498, 1229, 1197, 1169 cm<sup>-1</sup>.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.44 ("dt", J = 11.2, 2.3 Hz, 1H), 7.34 ("dt", J = 8.3, 6.5 Hz, 1H), 7.23 (ddd, J = 8.3, 2.1, 0.9 Hz, 1H), 6.86 (dddd, J = 8.2, 8.2, 2.5, 0.9 Hz, 1H), 4.88 (m, 1H), 4.39 (dd, J = 12.3, 3.8 Hz, 1H), 4.32 (dd, J = 12.3, 4.7 Hz, 1H), 4.13 ("t", J = 9.0 Hz, 1H), 3.82 (dd, J = 9.0, 6.1 Hz, 1H), 2.33 (t, J = 7.3 Hz, 2H), 1.63 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H).

35 MS *m/z* (relative intensity): 281 (33.1, M<sup>+</sup>), 193 (9.9), 180 (3.3), 150 (28.7), 148 (68.6).

137 (59.3), 123 (41.7), 95 (38.3), 43 (100).

HRMS  $m/z$ : 281.1068 (calc'd for  $C_{14}H_{16}FNO_4$ : 281.1063).

Anal. calc'd for  $C_{14}H_{16}FNO_4$ : C, 59.78; H, 5.73; N, 4.98.

Found: C, 59.98; H, 5.72; N, 4.88.

5 Preparation 13 (R)-3-(3-fluorophenyl)-5-(hydroxymethyl)-2-oxooxazolidine

A solution of Preparation 12 (2.789 g, 9.91 mmol) in methanol (10 mL) is treated with a 25 wt. % solution of sodium methoxide in methanol (57  $\mu$ L, 0.99 mmol) at ambient temperature. After 45 min TLC (5% methanol/chloroform) reveals the starting material is consumed. The reaction mixture is carefully quenched by the addition of 1 N HCl (0.99 mL, 0.99 mmol) and  
10 then concentrated in vacuo. Chromatography of the crude product over silica gel, eluting first with 1:1 hexane/ ethyl acetate and then ethyl acetate, affords 1.903 g (91%) of the title compound as a white solid with the following characteristics:

MP: 106.5-107.5°C.

$[\alpha]_D^{25}$  -66.8° (c 1.1,  $CH_3CN$ ).

15 IR (mineral oil mull): 3520, 1724, 1612, 1590, 1496, 1428, 1420, 1232, 1199  $cm^{-1}$ .

$^1H$ -NMR ( $CDCl_3$ , 300 MHz)  $\delta$  7.44 ("dt", J = 11.3, 2.3 Hz, 1H), 7.32 ("dt", J = 8.3, 6.5 Hz, 1H), 7.23 (ddd, J = 8.3, 2.1, 1.0 Hz, 1H), 6.84 (dddd, J = 8.2, 8.2, 2.5, 1.0 Hz, 1H), 4.77 (m, 1H), 4.07-3.96 (m, 3H), 3.76 (dd, J = 12.7, 3.9 Hz, 1H), 2.44 (br s, 1H).

MS  $m/z$  (relative intensity): 211 (100,  $M^+$ ), 180 (6.8), 136 (34.3), 124 (84.7), 95 (71.6).

20 HRMS  $m/z$  211.0641 (calc'd for  $C_{10}H_{10}FNO_3$ : 211.0645).

Anal. calc'd for  $C_{10}H_{10}FNO_3$ : C, 56.87; H, 4.77; N, 6.63.

Found: C, 56.85; H, 4.94; N, 6.56.

The enantiomeric excess of the oxazolidinone alcohol is determined by reacting it with (R)-(+)- $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenylacetic acid (DCC, DMAP,  $CH_2Cl_2$ , rt), and  
25 examining the  $^1H$ -NMR spectrum of the resultant Mosher ester. The %ee is estimated to be  $\geq$  95%.

Preparation 14 (R)-3-(3-fluorophenyl)-5-(hydroxymethyl)-2-oxooxazolidine

A solution of N-(carbobenzyloxy)-3-fluoroaniline (1.000 g, 4.08 mmol) in dry tetrahydrofuran (10 mL) is cooled with a dry ice/acetone bath to ca. -78°C and then *n*-  
30 butyllithium (1.87 mL of a 1.6 M solution in hexanes, 2.91 mmol) is added. (R)-glycidyl butyrate (0.420 g or 0.413 mL, 2.91 mmol) is then added via syringe and the cooling bath allowed to dissipate overnight, with the reaction mixture reaching ambient temperature. The reaction mixture is quenched by the careful addition of saturated aqueous ammonium chloride, the entire mixture transferred to a separatory funnel with dichloromethane washings, and the  
35 mixture extracted with dichloromethane. The combined organic extracts are dried over sodium sulfate, filtered and concentrated in vacuo to give an oil which is purified by chromatography

over silica gel, eluting with 10% acetonitrile/chloroform containing 1% methanol, to afford 0.555 g (90% based on glycidyl butyrate; 64% based on CBz derivative of the aniline) of the title compound as a white solid identical in all respects to an authentic sample obtained as described in the previous experimental procedure.

5 Preparation 15 (R)-[3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl 4-methylbenzenesulfonate

A solution of Preparation 14 (1.800 g, 8.52 mmol) in dry pyridine (10 mL) is cooled to ca. 5°C and then treated with *p*-toluenesulfonyl chloride (1.706 g, 8.95 mmol). The solution is left at this temperature overnight. TLC (5% methanol/chloroform or 1:1 hexane/ethyl acetate) indicates the starting material is consumed. The reaction mixture is dumped into ice water (30 mL) and the resultant precipitate collected by vacuum filtration through a medium-porosity sintered glass funnel. The collected solids are thoroughly washed with cold water, dried in vacuo, and recrystallized from ethyl acetate/hexane to give 2.743 g (88%) of the title compound as a white solid with the following characteristics:

15 MP: 114-115°C.

$[\alpha]_D^{25}$  -62.6° (c 1.0, CH<sub>3</sub>CN).

IR (mineral oil mull): 1751, 1617, 1591, 1499, 1415, 1362, 1227, 1202, 1191, 1172, 1093, 967 cm<sup>-1</sup>.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.78 ("d", J = 8.4 Hz, 2H), 7.38 ("dt", J = 11.2, 2.3 Hz, 1H), 7.36 ("d", J = 7.8 Hz, 2H), 7.33 ("dt", J = 8.3, 6.6 Hz, 1H), 7.16 (ddd, J = 8.3, 2.2, 1.0 Hz, 1H), 6.86 (dddd, J = 8.2, 8.2, 2.5, 1.0 Hz, 1H), 4.84 (m, 1H), 4.29 (dd, J = 11.1, 4.1 Hz, 1H), 4.24 (dd, J = 11.1, 4.6 Hz, 1H), 4.10 ("t", J = 9.1 Hz, 1H), 3.88 (dd, J = 9.2, 6.0 Hz, 1H), 2.46 (s, 3H).

MS *m/z* (relative intensity): 365 (70.6, M<sup>+</sup>), 149 (100), 122 (32.8), 91 (52.8).

25 HRMS *m/z* 365.0738 (calc'd for C<sub>17</sub>H<sub>16</sub>FNO<sub>5</sub>S: 365.0733).

Anal. calc'd for C<sub>17</sub>H<sub>16</sub>FNO<sub>5</sub>S: C, 55.88; H, 4.41; N, 3.83.

Found: C, 55.96; H, 4.38; N, 3.80.

Preparation 16 (R)-[3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl azide

A solution of the tosylate (Preparation 15; 2.340 g, 6.40 mmol) in dry DMF (60 mL) is treated with solid sodium azide (3.331 g, 51.23 mmol) at ambient temperature. The resultant slurry is warmed to 65°C for 4.5 h and then cooled to ambient temperature and left overnight. The reaction mixture is then diluted with ethyl acetate and water, transferred to a separatory funnel, and extracted with ethyl acetate. The combined ethyl acetate extracts are washed thoroughly with water, and then dried (sodium sulfate), filtered, and concentrated in vacuo to give 1.492 g (99%) of the "crude" azide as a white solid which is essentially pure. The following characteristics are noted:

MP: 81-82°C.

$[\alpha]_D^{25} -136.5^\circ$  (c 0.9, CHCl<sub>3</sub>).

IR (mineral oil mull): 2115, 1736, 1614, 1591, 1586, 1497, 1422, 1233, 1199, 1081, 1049 cm<sup>-1</sup>.

5 <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.45 ("dt", J = 11.2, 2.3 Hz, 1H), 7.34 ("dt", J = 8.3, 6.4 Hz, 1H), 7.23 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H), 6.86 (dddd, J = 8.2, 8.2, 2.5, 1.0 Hz, 1H), 4.81 (m, 1H), 4.09 ("t", J = 8.9 Hz, 1H), 3.86 (dd, J = 9.0, 6.2 Hz, 1H), 3.72 (dd, J = 13.2, 4.5 Hz, 1H), 3.60 (dd, J = 13.2, 4.4 Hz, 1H).

MS *m/z* (relative intensity): 236 (59.0, M<sup>+</sup>), 179 (94.9), 136 (59.5), 122 (62.4), 109  
10 (71.8), 95 (100), 75 (40.7).

HRMS *m/z* 236.0708 (calc'd for C<sub>10</sub>H<sub>9</sub>FN<sub>4</sub>O<sub>2</sub>: 236.0709).

Anal. calc'd for C<sub>10</sub>H<sub>9</sub>FN<sub>4</sub>O<sub>2</sub>: C, 50.85; H, 3.84; N, 23.72.

Found: C, 50.74; H, 3.76; N, 23.71.

Preparation 17 (S)-N-[[3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide

15 A solution of the azide (Preparation 16; 8.200 g, 34.71 mmol) in ethyl acetate (100 mL) is treated with 10% palladium on carbon (0.820 g) under nitrogen. The atmosphere is then replaced with hydrogen (balloon) via repeated evacuation and filling. After stirring under hydrogen for 17 h, TLC (5% methanol/chloroform) reveals the azide is consumed. The atmosphere is replaced with nitrogen and then pyridine (6 mL) and acetic anhydride (4.1 mL,  
20 43.40 mmol) are added to the reaction mixture. The reaction mixture is stirred for 1 h at ambient temperature and then filtered through Celite, washing the pad with ethyl acetate. The filtrate is concentrated in vacuo and the residue taken-up in dichloromethane. The addition of diethyl ether affords a precipitate. After standing in the refrigerator overnight the solids are collected by vacuum filtration, washed with cold hexane, and dried in vacuo to furnish 4.270 g  
25 of the title compound as a white solid. Another 3.700 g is obtained from the mother liquors for an overall yield of 91%. In another run, the crude product is purified by chromatography over silica gel, eluting with 5% methanol/chloroform. The following characteristics are noted:

MP: 140.0-140.5°C.

$[\alpha]_D^{25} -6.6^\circ$  (c 1.0, CHCl<sub>3</sub>).

30 Preparation 18 (S)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide

The oxazolidinone intermediate described in Preparation 17 (0.280 g, 1.11 mmol) is dissolved in a mixture of acetic acid (20 mL) and trifluoroacetic acid (5 mL) and then treated with iodine monochloride (2.343 g, 14.43 mmol) at ambient temperature. The dark red-brown mixture is stirred at room temperature under nitrogen. An orange precipitate gradually forms.  
35 After ca. 24 h the reaction mixture is diluted with diethyl ether and the solids collected by vacuum filtration through a medium-porosity sintered glass filter, washing with Et<sub>2</sub>O. The

crude solids are dissolved in hot chloroform (a little methanol is added to aid dissolution), transferred to a separatory funnel, and washed with saturated aqueous sodium bicarbonate, 20% aqueous sodium thiosulfate and brine. The organic phase is dried over sodium sulfate, filtered and concentrated in vacuo to afford 0.295 g (70%) of the title compound as a white solid. The

5 following characteristics are noted:

MP: 185.5-186.5°C.

$[\alpha]_D^{25}$  -37.6° (c 1.0, DMF).

Preparation 19 (±)-N-[[3-[3-fluoro-4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

10 In 1,4-dioxane (10 mL) is combined (±)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide (Preparation 18; 0.091 g, 0.24 mmol), bis(triphenylphosphine)-palladium(II) chloride (0.017 g, 0.024 mmol) and hexamethylditin (0.105 g, 0.321 mmol). The reaction mixture is thoroughly purged with nitrogen and heated to reflux temperature for 1.5 h. After this time, the reaction is concentrated under reduced pressure and then purified by silica  
15 gel chromatography (10 g of silica gel; eluted with 100 mL each of 0.5, 1, and finally 1.5% methanol/chloroform). After concentration of appropriate fractions, 0.100 g (100%) of the racemic title compound is obtained as a yellow solid with the following characteristics:

MP: 127-130°C.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz):  $\delta$  7.38-7.33 (m, 2H), 7.19 (dd,  $J = 8.0, 2.1$  Hz, 1H), 6.04  
20 (bs, 1H), 4.83-4.72 (m, 1H), 4.05 (dd,  $J = 9.1, 9.1$  Hz, 1H), 3.76 (dd,  $J = 9.2, 6.7$  Hz, 1H), 3.71-3.59 (m, 2H), 2.02 (s, 3H), 0.34 (d,  $J = 28.6$  Hz, 9H).

MS  $m/z$  (relative intensity): 415 (3,  $\text{M}^+$ ), 401 (100), 165 (10), 139 (15), 56 (24), 43 (41).

EXAMPLE 55 (±)-N-[[3-[3-fluoro-4-(6-quinolyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide.  
25

(±)-N-[[3-[3-fluoro-4-(trimethylstannyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (Preparation 19; 0.367 g, 0.88 mmol), 6-bromoquinoline (0.239 g, 1.15 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.062 g, 0.088 mmol) are combined with DMF (10 mL). The reaction mixture is thoroughly purged with nitrogen and then heated to 80°C under nitrogen.  
30 After 2 h, little progress is noted by TLC and so the reaction mixture is heated to 95°C for a further 2 h. At this point, TLC revealed the reaction is complete. The mixture is cooled to ambient temperature and concentrated under reduced pressure to give a crude material which is purified by chromatography over silica gel (10 g of silica gel; eluted with methanol/chloroform, 1→4%) to afford 0.136 g (51%) of the racemic title compound as an off-white solid with the  
35 following characteristics:

MP: 216-219°C (dec).



IR (internal reflectance): 3411, 3281, 1743, 1657, 1630, 1566, 1521, 1499, 1416, 1226, 1194  $\text{cm}^{-1}$ .

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz):  $\delta$  8.95 (dd,  $J = 4.2, 1.5$  Hz, 1H), 8.26-8.20 (m, 2H), 8.00 (br-s, 1H), 7.92 (d br t,  $J = 8.8, 2.0$  Hz, 1H), 7.61 (dd,  $J = 12.9, 2.1$  Hz, 1H), 7.57 ("t",  $J = 8.6$  Hz, 1H), 7.47 (dd,  $J = 8.2, 4.3$  Hz, 1H), 7.35 (dd,  $J = 8.5, 2.1$  Hz, 1H), 6.08 (b t,  $J = 6.0$  Hz, 1H), 4.84 (m, 1H), 4.13 ("t",  $J = 9.0$  Hz, 1H), 3.86 (dd  $J = 9.1, 6.8$  Hz, 1H), 3.80-3.62 (m, 2H), 2.05 (s, 3H).

MS  $m/z$  (relative intensity): 379 (100.0,  $\text{M}^+$ ), 335 (24.4), 307 (17.0), 276 (42.6), 264 (29.2), 251 (93.8).

10 EXAMPLE 56 (S)-N-[[3-[3-fluoro-4-(4-pyridyl)phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide

A slurry of the oxazolidinone iodide described in Preparation 18 (0.063 g, 0.165 mmol) and trimethyl(4-pyridyl)tin (0.060 g, 0.248 mmol) in 1,4-dioxane (5 mL) is degassed by repeated evacuation and filling with nitrogen. Bis(triphenylphosphine)palladium(II) chloride (0.012 g, 0.0165 mmol) is added, the reaction again degassed, and then the mixture is brought to reflux under nitrogen. After 4 h TLC (silica gel, 10% methanol/chloroform) reveals some of the iodide still remains. The mixture is refluxed a further 20 h, cooled to ambient temperature, and concentrated under reduced pressure. The residue is chromatographed over silica gel, eluting with a little chloroform and then methanol/chloroform (1%, 2%, and then 5%), to afford 0.046 g (84%) of the title compound as a white solid which is identical by  $^1\text{H-NMR}$  and chromatographic behavior to a fully characterized racemic sample. The following characteristics are noted for the enantiomerically enriched material:

MP: 190.5-191.0°C.

$[\alpha]_D^{25} -16.4^\circ$  (c 0.5,  $\text{CHCl}_3$ ).

25 The following characteristics are noted for a racemic sample:

MP: 179-180°C.

IR (internal reflectance): 3279, 3063, 1756, 1752, 1657, 1626, 1600, 1542, 1522, 1485, 1412, 1407, 1377, 1222, 1198  $\text{cm}^{-1}$ .

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  8.67 (dd,  $J = 6.1, 1.5$  Hz, 2H), 7.59 (dd,  $J = 13.1, 2.2$  Hz, 1H), 7.50 ("t",  $J = 8.5$  Hz, 1H), 7.47 (dd,  $J = 6.1, 1.4$  Hz, 2H), 7.33 (dd,  $J = 8.7, 2.2$  Hz, 1H), 6.15 (bt,  $J = 6.0$  Hz, 1H), 4.84 (m, 1H), 4.11 ("t",  $J = 9.1$  Hz, 1H), 3.85 (dd,  $J = 9.2, 6.7$  Hz, 1H), 3.78-3.62 (m, 2H), 2.04 (s, 3H).





MS  $m/z$  (relative intensity): 329 (39.8,  $\text{M}^+$ ), 285 (29.3), 257 (14.5), 201 (52.4), 172 (27.1), 73 (27.1), 42 (100.0).

35 Anal. calc'd for  $\text{C}_{17}\text{H}_{16}\text{FN}_3\text{O}_3$ : C, 62.00; H, 4.90; N, 12.76.

Found: C, 62.01; H, 4.84; N, 12.82.

-32-

## CHART A



-33-


## CHART A (continued)

5


10

15

20



(V)




(VI)

-34-


## CHART B

5




(VI)

10



(VII)


15



(VIII)

20

25




(IX)

-35-


## CHART B (continued)

5




(X)

10



(XI)

15




(XII)


20

## CHART C


5




(a) phenyl




(b) pyridyl




(c) pyrazinyl




(d) pyridazinyl




(e) pyrimidinyl



(f) 1,2,3-triazinyl




(g) 1,2,4-triazinyl




(h) 1,2,5-triazinyl

## CHART C (continued)

5




(i) quinolinyl




(j) isoquinolinyl

10




(k) quinoxaliny1




(l) quinazolinyl


15




(m) phthalaziny1




(n) cinnolinyl




(o) naphthyridiny1




(p) indoly1



(q) pyrrolopyridiny1




(r) furanopyridiny1




(s) thienopyridiny1

## CHART C (continued)

5



(t) benzothiazolyl




(v) benzoxazolyl


10



(v) imidazolyl




(w) pyrazolyl




(x) thiazolyl


15




(y) isothiazolyl



(z) oxazolyl



(aa) isoxazolyl




(bb) pyrrolyl




(cc) furanyl



(dd) thiophenyl




(ee) 1,2,3-triazolyl



(ff) 1,2,4-triazolyl




## CHART D



-40-

## CHART E




CLAIMS

We claim:

1. A substituted aryl- and heteroaryl-phenyl oxazolidinone of Formula (XII)

5



(XII)

10

where

- (I)  $R_1$  and  $R_2$  are the same or different and are selected from the group consisting of

- (a) -H,  
 (b) -F,  
 (c) -Cl,  
 (d) -CF<sub>3</sub>, and  
 (f) -OCH<sub>3</sub>, provided that only one of  $R_1$  or  $R_2$  may be hydrogen;

15

- (II)  $R_3$  is selected from the group consisting of

- (a) phenyl,  
 (b) pyridyl,  
 (c) pyrazinyl, (d) pyridazinyl, (e) pyrimidinyl,  
 (f) 1,2,3-, (g) 1,2,4-, (h) 1,2,5-triazinyl,  
 (i) quinolinyl, (j) isoquinolinyl,  
 (k) quinoxalinyl, (l) quinazolinyl, (m) phthalazinyl, (n) cinnolinyl,  
 (o) naphthyridinyl,

20

- (p) indolyl having nitrogen optionally substituted with  $R_{5-1}$  where  $R_{5-1}$  is

- H,  
 $C_1$ - $C_4$  alkyl optionally substituted with one or more halogens,  
 $C_3$ - $C_6$  cycloalkyl, or

25

- C(O) $R_{5-2}$  where  $R_{5-2}$  is

- H,  
 $C_1$ - $C_4$  alkyl optionally substituted with one or more halogens, or  
 phenyl optionally substituted with one or more halogens,

- (q) pyrrolopyridinyl having the saturated nitrogen substituted with  $R_{5-1}$  where

- $R_{5-1}$  is as defined above, (r) furanopyridinyl, (s) thienopyridinyl,

30

- (t) benzothiazolyl, (u) benzoxazolyl,

35

(v) imidazolyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

(w) pyrazolyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

5 (x) thiazolyl, (y) isothiazolyl,

(z) oxazolyl, (aa) isoxazolyl,

(bb) pyrrolyl having nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

(cc) furanyl, (dd) thiophenyl,

10 wherein substituents (a)-(dd) are optionally substituted with X and Y,

(ee) 1,2,3-, (ff) 1,2,4-triazolyl having the saturated nitrogen substituted with  $R_{5-1}$  where  $R_{5-1}$  is as defined above,

wherein substituents (ee) and (ff) are optionally substituted with X;

(III) each occurrence of Y is independently selected from

- 15 (a) -H,

(b) -F, (c) -Cl, (d) -Br, (e) -I,

(f)  $-R_{3-1}$ , (g)  $-OR_{3-1}$  where  $R_{3-1}$  is H or  $C_1-C_4$  alkyl, or

(h)  $-NO_2$ ;

(IV) each occurrence of X is independently selected from

20 (a) -H,

(b)  $C_1-C_8$  alkyl optionally substituted with

one or more halogens,

-OH,

=O other than at alpha position,

25  $-S(O)_n R_{3-2}$  where  $R_{3-2}$  is  $C_1-C_4$  alkyl or  $C_3-C_8$  cycloalkyl, or

$-NR_{3-3}R_{3-4}$  where  $R_{3-3}$  and  $R_{3-4}$  are the same or different and are -H,

$C_1-C_8$  alkyl,  $C_3-C_8$  cycloalkyl,  $-(CH_2)_t CHOR_{3-5}$ ,  $-(CH_2)_t NR_{3-6}R_{3-7}$ , or taken together are  $-(CH_2)_t O(CH_2)_t$ ,

$-(CH_2)_t CH(CO)R_{3-8}$ , or  $-(CH_2)_t N(R_{3-8})(CH_2)_2$  where

30  $R_{3-5}$  is -H or  $C_1-C_4$  alkyl, or

$R_{3-6}$  and  $R_{3-7}$  are the same or different and are -H,  $C_1-C_4$  alkyl

or taken together are  $-(CH_2)_t$ ,

(c)  $C_2-C_5$  alkenyl,

(d)  $C_3-C_8$  cycloalkyl,

35 (e)  $-OR_{3-3}$  where  $R_{3-3}$  is as defined above,


(f) -CN,

-43-


- (g)  $-S(O)_n-R_{3-8}$  where  $R_{3-8}$  is  
 $C_1-C_4$  alkyl optionally substituted with  
one or more halogens,  
-OH,  
5 -CN,  
 $-NR_{3-3}R_{3-4}$  where  $R_{3-3}$  and  $R_{3-4}$  are as defined above,  
 $-CO_2R_{3-5}$  where  $R_{3-5}$  is as defined above,  
 $C_2-C_4$  alkenyl,  
 $-NR_{3-9}R_{3-10}$  where  $R_{3-9}$  is -H,  $C_1-C_4$  alkyl, or  $C_3-C_8$  cycloalkyl and  
10  $R_{3-10}$  is -H,  $C_1-C_4$  alkyl,  $C_1-C_4$  alkenyl,  $C_3-C_4$  cycloalkyl,  $-OR_{3-5}$ , or  $-NR_{3-6}R_{3-7}$  where  
 $R_{3-5}$ ,  $R_{3-6}$ , and  $R_{3-7}$  are as defined above,  
 $-N_3$ ,  
 $-NHC(O)R_{3-11}$  where  $R_{3-11}$  is  $C_1-C_4$  alkyl optionally substituted with  
one or more halogens,  
15 (h)  $-S(O)_2-N=S(O)_pR_{3-14}R_{3-15}$  where  $R_{3-14}$  and  $R_{3-15}$  are the same or different  
and are  $C_1-C_2$  alkyl, or taken together are  $-(CH_2)_q-$ ,  
--(i)  $-S-C(O)-R_{3-11}$  where  $R_{3-11}$  is as defined above,  
(j) tetrazoly,  
(k)  $-NR_{3-3}R_{3-4}$  where  $R_{3-3}$  and  $R_{3-4}$  are as defined above,  
20 (l)  $-N(R_{3-3})COR_{3-11}$  where  $R_{3-3}$  and  $R_{3-11}$  are as defined above,  
(m)  $-N(R_{3-3})S(O)_nR_{3-11}$  where  $R_{3-3}$  and  $R_{3-11}$  are as defined above,  
(n)  $-CONR_{3-3}R_{3-4}$  where  $R_{3-3}$  and  $R_{3-4}$  are as defined above,  
(o)  $-C(O)R_{3-16}$  where  $R_{3-16}$  is  
-H,  
25  $C_1-C_8$  alkyl optionally substituted with one or more halogens.  
 $C_1-C_4$  alkyl optionally substituted with  
 $-OR_{3-5}$ ,  
 $-OC(O)R_{3-5}$ ,  
 $-NR_{3-3}R_{3-4}$ ,  
30  $-S(O)_nR_{3-17}$ ,  
 $C_3-C_8$  cycloalkyl, or  
 $C_2-C_5$  alkenyl optionally substituted with -CHO or  $-CO_2R_{3-5}$ , where  
 $R_{3-3}$ ,  $R_{3-4}$ , and  $R_{3-5}$  are as defined above and  $R_{3-17}$  is  $C_1-C_4$  alkyl or  $C_3-C_8$  cycloalkyl,  
(p)  $-C(=NR_{3-18})R_{3-16}$  where  $R_{3-16}$  is as defined above and  $R_{3-18}$  is  
35  $-NR_{3-3}R_{3-4}$ ,  $-OR_{3-3}$ , or  $-NHC(O)R_{3-3}$  where  $R_{3-3}$  and  $R_{3-4}$  are as defined above,  
(q)  $-CR_{3-16}(OR_{3-19})OR_{3-20}$  where  $R_{3-16}$  is as defined above and  $R_{3-19}$  and

-44-

$R_{3-20}$  are the same or different and are  $C_1-C_4$  alkyl, or taken together are  $-(CH_2)_m-$ .



10



20 where  $R_{3-3}$ ,  $R_{3-4}$ ,  $R_{3-5}$ ,  $R_{3-9}$ , and  $R_{3-16}$  are as defined above and  $R_{3-21}$  is  $R_{3-4}$  or  $-NR_{3-4}R_{3-5}$  where  $R_{3-4}$  and  $R_{3-5}$  are as defined above,

m is 2 or 3;

n is 0, 1, or 2;

p is 0 or 1;

25 q is 3, 4 or 5;

t is 1, 2 or 3;

(V)  $R_4$  is selected from the group consisting of

(a) -H,

(b)  $C_1-C_{12}$  alkyl optionally substituted with 1-3 Cl,

30 (c)  $C_3-C_{12}$  cycloalkyl,

(d)  $C_5-C_{12}$  alkenyl containing one double bond,

(e) phenyl optionally substituted with 1-3 -OH, -OCH<sub>3</sub>, -OC<sub>2</sub>H<sub>5</sub>, -NO<sub>2</sub>, -F,

-Cl, -Br, -COOH and -SO<sub>3</sub>H, -N(R<sub>4-1</sub>)(R<sub>4-2</sub>) where R<sub>4-1</sub> and R<sub>4-2</sub> are the same or different and are -H and  $C_1-C_5$  alkyl,

35 (f) furanyl,

(g) tetrahydrofuranyl,

(h) 2-thiophene,

(i) pyrrolidinyl,

(j) pyridinyl,

40 (k) -O-R<sub>4-3</sub> where R<sub>4-3</sub> is  $C_1-C_4$  alkyl,

(l) -NH<sub>2</sub>.

-45-

(m)  $\text{-NHR}_{4-4}$  where  $\text{R}_{4-4}$  is  $\text{C}_1\text{-C}_3$  alkyl or  $-\phi$ ,

(n)  $\text{-NR}_{4-4}\text{R}_{4-5}$  where  $\text{R}_{4-4}$  is as defined above and  $\text{R}_{4-5}$  is  $\text{C}_1\text{-C}_3$  alkyl, or taken together with the attached nitrogen atom to form a saturated mono-nitrogen  $\text{C}_5\text{-C}_7$  heterocyclic ring including  $-\text{O}-$  (morpholine),

5 (o)  $-\text{CH}_2\text{-OH}$ ,

(p)  $-\text{CH}_2\text{-OR}_{4-6}$  where  $\text{R}_{4-6}$  is  $\text{C}_1\text{-C}_4$  alkyl or  $-\text{CO-R}_{4-7}$  where  $\text{R}_{4-7}$  is  $\text{C}_1\text{-C}_4$  alkyl or  $-\phi$ ;

and pharmaceutically acceptable salts thereof.

10 2. A compound according to claim 1 where one of  $\text{R}_1$  or  $\text{R}_2$  are hydrogen.

3. A compound according to claim 2 where  $\text{R}_3$  is phenyl optionally substituted with X and Y.

15 4. A compound according to claim which is

$(\pm)\text{-5-(acetamidomethyl)-3-(4-phenyl-3-fluorophenyl)-2-oxazolidinone}$ ,

$(\text{S})\text{-N-}[[3\text{-[3-fluoro-4-(4-pyridyl)phenyl]-2-oxo-5-oxazolidinyl}]\text{methyl}]\text{acetamide}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-(4-phenyl-3-chlorophenyl)-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-phenyl-3-(trifluoromethyl)phenyl]-2-oxazolidinone}$ ,

20  $(\pm)\text{-5-(acetamidomethyl)-3-(4-phenyl-3-methoxyphenyl)-2-oxazolidinone}$ , and

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(4-(dimethylamino)phenyl)-3-fluorophenyl]-2-oxazolidinone}$ .

5. A compound according to claim 2 where  $\text{R}_3$  is pyridyl optionally substituted with X  
25 and Y.

6. A compound according to claim 5 which is

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-fluorophenyl]-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-chlorophenyl]-2-oxazolidinone}$ ,

30  $(\pm)\text{-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-(trifluoromethyl)phenyl]-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3-methoxyphenyl]-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-fluorophenyl]-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-chlorophenyl]-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-(trifluoromethyl)phenyl]-2-oxazolidinone}$ ,

35  $(\pm)\text{-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3-methoxyphenyl]-2-oxazolidinone}$ ,

$(\pm)\text{-5-(acetamidomethyl)-3-[4-(2,6-dimethylpyridin-4-yl)-3-fluorophenyl]-2-oxazolidinone}$ .

oxazolidinone,

(±)-5-(acetamidomethyl)-3-[4-(2-methylpyridin-4-yl)-3-fluorophenyl]-2-oxazolidinone,

and

(±)-5-(acetamidomethyl)-3-[4-(2-ethylpyridin-4-yl)-3-fluorophenyl]-2-oxazolidinone.

5

7. A compound according to claim 2 where R<sub>3</sub> is quinoliny or isoquinoliny optionally substituted with X and Y.

8. A compound according to claim 7 which is

10

(±)-5-(acetamidomethyl)-3-[4-(3-quinolyl)-3-fluorophenyl]-2-oxazolidinone,

(±)-5-(acetamidomethyl)-3-[4-(4-quinolyl)-3-fluorophenyl]-2-oxazolidinone,

(±)-5-(acetamidomethyl)-3-[4-(6-quinolyl)-3-fluorophenyl]-2-oxazolidinone, and

(±)-5-(acetamidomethyl)-3-[4-(4-isoquinolyl)-3-fluorophenyl]-2-oxazolidinone.

15

9. A compound according to claim 2 where R<sub>3</sub> is indolyl having nitrogen optionally substituted with R<sub>5</sub>, 1 and optionally substituted with X and Y.

10. A compound according to claim 9 which is

20

(±)-5-(acetamidomethyl)-3-[4-(5-indolyl)-3-fluorophenyl]-2-oxazolidinone, and

(±)-5-(acetamidomethyl)-3-[4-(1-methyl-5-indolyl)-3-fluorophenyl]-2-oxazolidinone.

11. A compound according to claim 2 where R<sub>3</sub> is benzothiazolyl or benzoxazolyl optionally substituted with X and Y.

25

12. A compound according to claim 11 which is

(±)-5-(acetamidomethyl)-3-[4-(6-benzothiazolyl)-3-fluorophenyl]-2-oxazolidinone, and

(±)-5-(acetamidomethyl)-3-[4-(6-benzoxazolyl)-3-fluorophenyl]-2-oxazolidinone.

30

13. A compound according to claim 2 where R<sub>3</sub> is thiazolyl or oxazolyl optionally substituted with X and Y.

14. A compound according to claim 13 which is

(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-thiazolyl)-3-fluorophenyl]-2-oxazolidinone, and

(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-oxazolyl)-3-fluorophenyl]-2-oxazolidinone.

35



15. A compound according to claim 1 where  $R_1$  and  $R_2$  are other than hydrogen.
16. A compound according to claim 15 where  $R_3$  is phenyl optionally substituted with X and Y.
- 5 17. A compound according to claim 16 which is  
(±)-5-(acetamidomethyl)-3-(4-phenyl-3,5-difluorophenyl)-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-(4-phenyl-3,5-dichlorophenyl)-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-phenyl-3,5-bis(trifluoromethyl)phenyl]-2-oxazolidinone,  
10 (±)-5-(acetamidomethyl)-3-(4-phenyl-3,5-dimethoxyphenyl)-2-oxazolidinone, and  
(±)-5-(acetamidomethyl)-3-[4-(4-(dimethylamino)phenyl)-3,5-difluorophenyl]-2-oxazolidinone.
18. A compound according to claim 15 where  $R_3$  is pyridyl optionally substituted with X and Y.
- 15 19. A compound according to claim 18 which is  
(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone,  
20 methanesulfonic acid salt,  
(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-dichlorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-bis(trifluoromethyl)phenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(3-pyridyl)-3,5-dimethoxyphenyl]-2-oxazolidinone,  
25 (±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-difluorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-dichlorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-bis(trifluoromethyl)phenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(4-pyridyl)-3,5-dimethoxyphenyl]-2-oxazolidinone,  
30 (±)-5-(acetamidomethyl)-3-[4-(2,6-dimethylpyridin-4-yl)-3,5-difluorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(2-methylpyridin-4-yl)-3,5-difluorophenyl]-2-oxazolidinone, and  
(±)-5-(acetamidomethyl)-3-[4-(2-ethylpyridin-4-yl)-3,5-difluorophenyl]-2-oxazolidinone.
- 35 20. A compound according to claim 15 where  $R_3$  is quinolinyl or isoquinolinyl optionally

substituted with X and Y.

21. A compound according to claim 20 which is  
(±)-5-(acetamidomethyl)-3-[4-(3-quinolyl)-3,5-difluorophenyl]-2-oxazolidinone,  
5 (±)-5-(acetamidomethyl)-3-[4-(4-quinolyl)-3,5-difluorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(6-quinolyl)-3,5-difluorophenyl]-2-oxazolidinone, and  
(±)-5-(acetamidomethyl)-3-[4-(4-isoquinolyl)-3,5-difluorophenyl]-2-oxazolidinone.
22. A compound according to claim 15 where R<sub>3</sub> is indolyl having nitrogen optionally  
10 substituted with R<sub>5-1</sub> and optionally substituted with X and Y.
23. A compound according to claim 22 which is  
(±)-5-(acetamidomethyl)-3-[4-(5-indolyl)-3,5-difluorophenyl]-2-oxazolidinone, and  
(±)-5-(acetamidomethyl)-3-[4-(1-methyl-5-indolyl)-3,5-difluorophenyl]-2-oxazolidinone.  
15
24. A compound according to claim 15 where R<sub>3</sub> is benzothiazolyl or benzoxazolyl  
optionally substituted with X and Y.
25. A compound according to claim 24 which is  
20 (±)-5-(acetamidomethyl)-3-[4-(6-benzothiazolyl)-3,5-difluorophenyl]-2-oxazolidinone,  
and  
(±)-5-(acetamidomethyl)-3-[4-(6-benzoxazolyl)-3,5-difluorophenyl]-2-oxazolidinone.
26. A compound according to claim 15 where R<sub>3</sub> is thiazolyl or oxazolyl optionally  
25 substituted with X and Y.
27. A compound according to claim 26 which is  
(±)-5-(acetamidomethyl)-3-[4-(2-dimethylamino)-4-thiazolyl]-3,5-difluorophenyl]-2-  
oxazolidinone,  
30 (±)-5-(acetamidomethyl)-3-[4-(2-amino-4-thiazolyl)-3,5-difluorophenyl]-2-oxazolidinone,  
(±)-5-(acetamidomethyl)-3-[4-(2-(dimethylamino)-4-oxazolyl)-3,5-difluorophenyl]-2-  
oxazolidinone, and  
(±)-5-(acetamidomethyl)-3-[4-(2-amino-4-oxazolyl)-3,5-difluorophenyl]-2-oxazolidinone.
- 35 28. A process for making a compound of formula (XII) comprising:  
(a) converting a substituted aniline to a stabase derivative,

-49-

(b) treating the stabase derivative to form an aryl- or heteroaryl-substituted aniline,  
and

(c) converting the aryl- or heteroaryl-substituted aniline to a aryl- or heteroaryl-  
substituted phenyloxazolidinone.

5

29. A process for making an oxazolidinone iodide comprising reacting a carbobenzyloxy  
allyl compound in the presence of an excess of pyridine and iodine, said excess being of equal  
amounts of 2-20 molar equivalents.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 92/08267

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07D263/20; C07D413/10; C07D417/10; A61K31/42 A61K31/44; A61K31/47; A61K31/425																					
<b>II. FIELDS SEARCHED</b> Minimum Documentation Searched <sup>7</sup> <table border="1"> <tr> <th>Classification System</th> <th>Classification Symbols</th> </tr> <tr> <td>Int.Cl. 5</td> <td>C07D</td> </tr> </table> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>				Classification System	Classification Symbols	Int.Cl. 5	C07D														
Classification System	Classification Symbols																				
Int.Cl. 5	C07D																				
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1"> <tr> <th>Category<sup>o</sup></th> <th>Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th>Relevant to Claim No.<sup>13</sup></th> </tr> <tr> <td>X</td> <td>EP,A,0 352 781 (E.I. DU PONT DE NEMOURS AND COMPANY) 31 January 1990 cited in the application see claims</td> <td>1</td> </tr> <tr> <td>X</td> <td>EP,A,0 316 594 (E.I. DU PONT DE NEMOURS AND COMPANY) 24 May 1989 cited in the application see claims</td> <td>1</td> </tr> <tr> <td>X</td> <td>EP,A,0 127 902 (E.I. DU PONT DE NEMOURS AND COMPANY) 12 December 1984 cited in the application see claims</td> <td>1</td> </tr> <tr> <td colspan="2" style="text-align: center;">---</td> <td></td> </tr> <tr> <td colspan="2" style="text-align: center;">-/--</td> <td></td> </tr> </table>				Category <sup>o</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	EP,A,0 352 781 (E.I. DU PONT DE NEMOURS AND COMPANY) 31 January 1990 cited in the application see claims	1	X	EP,A,0 316 594 (E.I. DU PONT DE NEMOURS AND COMPANY) 24 May 1989 cited in the application see claims	1	X	EP,A,0 127 902 (E.I. DU PONT DE NEMOURS AND COMPANY) 12 December 1984 cited in the application see claims	1	---			-/--		
Category <sup>o</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>																			
X	EP,A,0 352 781 (E.I. DU PONT DE NEMOURS AND COMPANY) 31 January 1990 cited in the application see claims	1																			
X	EP,A,0 316 594 (E.I. DU PONT DE NEMOURS AND COMPANY) 24 May 1989 cited in the application see claims	1																			
X	EP,A,0 127 902 (E.I. DU PONT DE NEMOURS AND COMPANY) 12 December 1984 cited in the application see claims	1																			
---																					
-/--																					
<sup>o</sup> Special categories of cited documents : <sup>10</sup> <table border="0"> <tr> <td style="vertical-align: top;"> <b>"A"</b> document defining the general state of the art which is not considered to be of particular relevance  <b>"E"</b> earlier document but published on or after the international filing date  <b>"L"</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  <b>"O"</b> document referring to an oral disclosure, use, exhibition or other means  <b>"P"</b> document published prior to the international filing date but later than the priority date claimed         </td> <td style="vertical-align: top;"> <b>"T"</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  <b>"X"</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step  <b>"Y"</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  <b>"&amp;"</b> document member of the same patent family         </td> </tr> </table>				<b>"A"</b> document defining the general state of the art which is not considered to be of particular relevance <b>"E"</b> earlier document but published on or after the international filing date <b>"L"</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <b>"O"</b> document referring to an oral disclosure, use, exhibition or other means <b>"P"</b> document published prior to the international filing date but later than the priority date claimed	<b>"T"</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <b>"X"</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step <b>"Y"</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. <b>"&amp;"</b> document member of the same patent family																
<b>"A"</b> document defining the general state of the art which is not considered to be of particular relevance <b>"E"</b> earlier document but published on or after the international filing date <b>"L"</b> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <b>"O"</b> document referring to an oral disclosure, use, exhibition or other means <b>"P"</b> document published prior to the international filing date but later than the priority date claimed	<b>"T"</b> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <b>"X"</b> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step <b>"Y"</b> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. <b>"&amp;"</b> document member of the same patent family																				
<b>IV. CERTIFICATION</b> <table border="1"> <tr> <td>Date of the Actual Completion of the International Search  04 DECEMBER 1992</td> <td>Date of Mailing of this International Search Report  23. 12. 92</td> </tr> <tr> <td>International Searching Authority  EUROPEAN PATENT OFFICE</td> <td>Signature of Authorized Officer  HENRY J.C.</td> </tr> </table>				Date of the Actual Completion of the International Search  04 DECEMBER 1992	Date of Mailing of this International Search Report  23. 12. 92	International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  HENRY J.C.														
Date of the Actual Completion of the International Search  04 DECEMBER 1992	Date of Mailing of this International Search Report  23. 12. 92																				
International Searching Authority  EUROPEAN PATENT OFFICE	Signature of Authorized Officer  HENRY J.C.																				

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	<p>JOURNAL OF MEDICINAL CHEMISTRY vol. 33, no. 9, September 1990, WASHINGTON US pages 2569 - 2578 WALTER A.GREGORY ET AL 'Antibacterials.Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines.2The A group' cited in the application see the whole document -----</p>	1

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/08267

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
The formulation of claim 1 is so complicated because of the distinct combinations of the meanings of the variable parts that it does not comply with Art 6 PCT prescribing that the claims shall be clean and concise. For these reasons the search has been limited to the examples
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT**  
**ON INTERNATIONAL PATENT APPLICATION NO. US 9208267**  
**SA 65261**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 04/12/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0352781	31-01-90	US-A- 4948801	14-08-90
		AU-B- 622465	09-04-92
		AU-A- 3911589	01-02-90
		JP-A- 2124877	14-05-90
		US-A- 5130316	14-07-92
		US-A- 5043443	27-08-91
EP-A-0316594	24-05-89	AU-A- 2404388	27-04-89
		JP-A- 1135777	29-05-89
		US-A- 4977173	11-12-90
EP-A-0127902	12-12-84	AU-B- 583250	27-04-89
		AU-A- 2909984	13-12-84
		CA-A- 1254213	16-05-89
		CA-A- 1275652	30-10-90
		DE-A- 3485162	21-11-91
		JP-A- 60008277	17-01-85
		SU-A- 1505442	30-08-89
		SU-A- 1426451	23-09-88
		US-A- 4705799	10-11-87